

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
5 August 2004 (05.08.2004)

PCT

(10) International Publication Number
WO 2004/065558 A2

(51) International Patent Classification⁷:

C12N

(21) International Application Number:

PCT/US2004/001568

(22) International Filing Date: 16 January 2004 (16.01.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/440,424 16 January 2003 (16.01.2003) US

(71) Applicant (*for all designated States except US*): **NORTH CAROLINA STATE UNIVERSITY [US/US]**; 2401 Research Drive, Suite 1122, Campus Box 8210, Raleigh, NC 27695-8210 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **PETITTE, James, N.** [US/US]; 620 Shadywood Lane, Raleigh, NC 27603 (US). **PARDUE, Samuel, Lloyd** [US/US]; 6020 Fordland Drive, Raleigh, NC 27606 (US).

(74) Agent: **TAYLOR, Arles, A.**; Jenkins, Wilson & Taylor, P.A., Suite 1400, University Tower, 3100 Tower Boulevard, Durham, NC 27707 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 2004/065558 A2

(54) Title: DEPLETION OF ENDOGENOUS PRIMORDIAL GERM CELLS IN AVIAN SPECIES

(57) Abstract: Methods for modulating primordial germ cell (PGC) numbers and/or development in avians are provided. In one embodiment, the presently disclosed subject matter provides a method for modulating primordial germ cells numbers in an avian embryo comprising immunizing a female bird with an antigen associated with primordial germ cells, whereby an egg produced by the female bird comprises a sufficiently high concentration of antibodies specific for the antigen to modulate numbers of endogenous PGCS in an avian embryo present within the egg. Also provided are methods for producing chimeric avians, methods for increasing the proportion of male birds in a plurality of eggs, methods of producing avian gametes, and methods for enhancing germ line transmission of nucleic acids in birds.

DescriptionDEPLETION OF ENDOGENOUS PRIMORDIAL GERM CELLS
IN AVIAN SPECIESCross Reference to Related Application

5 This application claims the benefit of U.S. Provisional Patent Application Serial No. 60/440,424, filed January 16, 2003, the disclosure of which is incorporated herein by reference in its entirety.

Technical Field

10 The presently disclosed subject matter relates to methods for modulating primordial germ cell numbers in an avian. More particularly, the presently disclosed subject matter relates to the use of antibodies that bind to antigens associated with primordial germ cells to modulate the development of primordial germ cells during embryogenesis in avians. Donor primordial germ cells can be administered to avian embryos present 15 within eggs produced by birds treated with the presently disclosed methods to create chimeric avians.

Background Art

Chimeras are composite organisms comprising cells derived from more than one zygote. Experimental chimeras have been used to study cell-to-cell interactions and perform cell fate and lineage analyses during 20 development (McLaren, Mammalian Chimeras. Cambridge University Press, Cambridge, England, United Kingdom, 1976). The use of cells isolated from very early embryos to produce chimeras can result in organisms that develop with a full complement of somatic tissues partially made up of 25 descendants of the isolated cells. If the starting material includes early germ cells or their precursors, the resulting chimeras can produce gametes of both the donor and recipient genotypes. In addition, chimeras can be intraspecific (*i.e.* containing cells derived from two or more zygotes of the same species) or interspecific (*i.e.* containing cells derived from zygotes from at least two 30 different species).

The efficiency of generating germline chimeras by repopulating the gonads with the desired donor PGCs can be enhanced by reducing the

number of PGCs in the recipient organism. A number of approaches to reduce PGCs have been utilized with varying degrees of success. Continuous exposure to gamma irradiation (0.3-3.4 R/hr of ^{60}Co for 20 days) resulted in the complete destruction of oocytes at a dosage level of 3.4 and 5 1.8 R/hr (Mraz & Woody, *Radiation Res* 54:63-68, 1973). However, hatching frequency was reduced at levels of 0.9 R/hr or higher. The application of continuous low-level gamma irradiation to reduce endogenous PGC numbers is limited due to the relatively small numbers of eggs that can be exposed at any one time, the long period of exposure required, and also the 10 potentially teratogenic effects of the irradiation itself.

Short-term exposure to a gamma source has also been attempted (Carsience *et al.*, *Development* 117:669-75, 1993; Thoraval *et al.*, *Poultry Sci* 73:1897-1905, 1994; Maeda *et al.*, *Poultry Sci* 77:905-07, 1998). In these studies, unincubated eggs were exposed to 500-700 rads just prior to 15 the injection of stage X blastodermal or area pellucida cells. The incidence of germline chimerism following short-term gamma irradiation was highly variable. The basis for the inconsistent results was ascribed to "donor cells being injected into an inappropriate location..." (Carsience *et al.*, *Development* 117:669-75, 1993).

20 Attempts to sterilize recipient embryos using ultraviolet (UV) light have also been described (Reynaud, *J Embryol Exp Morphol* 21:485-507, 1969; Reynaud, *J Roux's Arch Devel Biol* 179:85-110, 1976; Aige-Gil & Simkiss, *Br Poult Sci* 32:427-438, 1991). Aige-Gil & Simkiss concluded "it is not possible to irradiate the germinal crescent, particularly at stage 4 of incubation, 25 without inducing major abnormalities". The degree of sterility appeared to be positively correlated with developmental abnormalities, thus limiting the practical use of UV-light as a means to reduce endogenous PGC.

The generation of germ line chimeras produces several potential benefits both to mankind and to the various avian species themselves. 30 Germ line chimeras can be used as a source of gametes with desirable characteristics, which can then be used in conjunction with breeding

programs to augment the avian gene pool. The ability to more easily produce gametes of particular avian species would be useful to the avian veterinary and poultry production fields. For endangered species such as the whooping crane, it would be extremely useful to have a ready supply of 5 male spermatozoa. For commercial birds such as turkeys, it would be desirable to more quickly and economically produce male spermatozoa. For meat-producing flocks, it is desirable to have ways to increase the ratio of male birds in the flock. As such, there is a need for new ways to obtain avian spermatozoa.

10 Accordingly, there remains a long-felt and continuing need for ways to increase the efficiency of the production of germ line chimeras in avians. The presently disclosed subject matter addresses this and other needs in the art.

Summary

15 The presently disclosed subject matter provides methods for modulating primordial germ cells numbers in an avian embryo. In one embodiment, the method comprises immunizing a female bird with an antigen associated with primordial germ cells, whereby an egg produced by the female bird comprises a sufficiently high concentration of antibodies 20 specific for the antigen to modulate numbers of endogenous PGCs in an avian embryo present within in the egg. In one embodiment, the female bird is selected from the group consisting of chicken, turkey, duck, quail, and sand hill crane. In another embodiment, the female bird is a chicken. In one embodiment, the antigen comprises an epitope of a polypeptide selected 25 from the group consisting of SSEA-1, VASA, EMA-1, germ cell-less, dead end, nanos, stella, fragilis, and DAZL. In one embodiment, the immunizing step results in a decrease in primordial germ cell numbers in the avian embryo. In another embodiment, the immunizing step results in an increase in primordial germ cell numbers in the avian embryo.

30 The presently disclosed subject matter also provides a method for modulating primordial germ cell development in an avian embryo. In one

embodiment, the method comprises immunizing a female bird with an antigen associated with primordial germ cells, whereby an egg produced by the female bird comprises a sufficiently high concentration of antibodies specific for the antigen to modulate development of PGCs in an avian
5 embryo present within the egg. In one embodiment, the antigen comprises an epitope of a polypeptide selected from the group consisting of SSEA-1, VASA, EMA-1, germ cell-less, dead end, nanos, stella, fragilis, and DAZL. In one embodiment, the female bird is selected from the group consisting of chicken, turkey, duck, quail, and sand hill crane. In another embodiment, the
10 female bird is a chicken. In one embodiment, the immunizing step results in an inhibition of development of the primordial germ cells in the avian embryo. In another embodiment, the immunizing step results in an enhancement of development of the primordial germ cells in the avian embryo.

The presently disclosed subject matter also provides a method for
15 producing a chimeric avian. In one embodiment, the method comprises (a) immunizing a female avian with an antigen associated with primordial germ cells; (b) producing an egg from the female bird, wherein the egg comprises a sufficiently high concentration of antibodies specific for the antigen to modulate PGC development, PGC numbers, or combinations thereof, in a
20 recipient embryo present within the egg; and (c) administering donor PGCs to the recipient embryo *in ovo* to produce a chimeric avian. In one embodiment, the antigen comprises an epitope of a polypeptide selected from the group consisting of SSEA-1, VASA, EMA-1, germ cell-less, dead end, nanos, stella, fragilis, and DAZL. In one embodiment, the donor PGCs
25 are from the same avian species as the recipient embryo. In another embodiment, the donor PGCs are from a different avian species as the recipient embryo. In one embodiment, the method further comprises incubating the chimeric avian to hatch.

In one embodiment of the instant method, the female avian is selected
30 from the group consisting of chicken, turkey, duck, quail, and sand hill crane. In one embodiment, the donor PGCs are from an avian embryo selected

from the group consisting of chicken, turkey, duck, quail, and whooping crane. In another embodiment, the donor PGCs carry a pair of male determinative (Z) chromosomes. In still another embodiment, the donor PGCs are selected from the group consisting of gonadal PGCs, blood PGCs, 5 and germinal crescent PGCs.

In still another embodiment, the donor PGCs carry a female determinative (w) chromosome. In one embodiment, the administering is by *in ovo* injection. In one embodiment, the donor PGCs are administered when the recipient embryo is between about stage IX according to the Eyal-Giladi & Kochav staging system and about stage 30 according to the Hamburger & Hamilton staging system. In another embodiment, the donor PGCs are administered when the recipient embryo is after stage 14 according to the Hamburger & Hamilton staging system. In still another embodiment, the administering step is carried out by injecting the recipient embryo with blastodermal cells, and wherein the blastodermal cells differentiate into donor PGCs in the recipient embryo.

The presently disclosed subject matter also provides a method for increasing the proportion of male birds in a plurality of bird eggs. In one embodiment, the method comprises (a) immunizing a female bird with an antigen associated with primordial germ cells; (b) producing an egg from the female bird, whereby the egg comprises a sufficiently high concentration of antibodies specific for the antigen to modulate PGC development in a recipient female bird present within the egg; (c) administering male (ZZ) PGCs to the recipient female bird *in ovo*; (d) incubating the recipient female bird to hatch; (e) raising the recipient female bird to sexual maturity; and (f) producing from the recipient female bird a plurality of bird eggs, wherein the proportion of male birds in the plurality of bird eggs produced by the recipient female bird is higher than would have been obtained in the absence of administering the male (ZZ) PGCs to the recipient female bird *in ovo*. In one embodiment, the antigen comprises an epitope of a polypeptide selected 20 from the group consisting of SSEA-1, VASA, EMA-1, germ cell-less, dead 25 30

end, nanos, stella, fragilis, and DAZL. In one embodiment, the female avian is selected from the group consisting of chicken, turkey, duck, quail, and sand hill crane. In one embodiment, the donor PGCs are from the same avian species as the recipient embryo. In another embodiment, the donor 5 PGCs are from a different avian species as the recipient embryo. In another embodiment, the PGCs are selected from the group consisting of gonadal PGCs, blood PGCs, and germinal crescent PGCs. In yet another embodiment, the donor PGCs are from an avian embryo selected from the group consisting of chicken, turkey, duck, quail, and whooping crane.

10 In one embodiment of the instant method, the administering is by *in ovo* injection. In another embodiment, the donor PGCs are administered when the recipient embryo is between about stage IX according to the Eyal-Giladi & Kochav staging system and about stage 30 according to the Hamburger & Hamilton staging system. In another embodiment, the donor 15 PGCs are administered when the recipient embryo is after stage 14 according to the Hamburger & Hamilton staging system. In still another embodiment, the administering step is carried out by injecting the recipient embryo with blastodermal cells, and wherein the blastodermal cells differentiate into donor PGCs in the recipient female bird.

20 The presently disclosed subject matter also provides a method for producing avian gametes from a second avian species in a first avian species. In one embodiment, the method comprises (a) immunizing a female of the first avian species with an antigen associated with primordial germ cells, whereby an egg produced by the female comprises a sufficiently 25 high concentration of antibodies specific for the antigen to modulate PGC development of a recipient bird of the first avian species present within the egg; (b) introducing donor PGCs isolated from an avian of the second avian species into the recipient bird of the first avian species; (c) incubating the recipient bird of the first avian species to hatch; and (d) raising the recipient 30 bird of the first avian species to sexual maturity, wherein the recipient bird of the first avian species produces gametes from the second avian species. In

one embodiment, the antigen comprises an epitope of a polypeptide selected from the group consisting of SSEA-1, VASA, EMA-1, germ cell-less, dead end, nanos, stella, fragilis, and DAZL. In one embodiment, the first avian species and the second avian species are each selected from the 5 group consisting of chicken, turkey, duck, quail, sand hill crane, and whooping crane. In one embodiment, the first avian species and the second avian species are the same. In another embodiment, the first avian species and the second avian species are different.

In one embodiment of the instant method, the administering is by *in ovo* injection. In one embodiment, the donor PGCs are administered when the recipient bird of the first avian species is between about stage IX according to the Eyal-Giladi & Kochav staging system and about stage 30 according to the Hamburger & Hamilton staging system. In another embodiment, the donor PGCs are administered when the recipient bird of 15 the first avian species is after stage 14 according to the Hamburger & Hamilton staging system. In still another embodiment, the administering step is carried out by injecting the recipient bird of the first avian species with blastodermal cells, and wherein the blastodermal cells differentiate into donor PGCs in the recipient bird of the first avian species. In one 20 embodiment, the PGCs are selected from the group consisting of gonadal PGCs, blood PGCs, and germinal crescent PGCs.

The presently disclosed subject matter also provides a method for enhancing germ line transmission of a nucleic acid molecule in a bird. In one embodiment, the method comprises (a) immunizing a female bird with 25 an antigen associated with primordial germ cells, whereby an egg produced by the female bird comprises a sufficiently high concentration of antibodies specific for the antigen to modulate PGC development in a recipient bird present within the egg; (b) administering a plurality of donor PGCs comprising the nucleic acid molecule to the recipient bird under conditions 30 sufficient to allow at least one of the plurality of PGCs to colonize a gonad of the recipient bird; (c) incubating the recipient bird to hatch; and (d) raising

the recipient bird to sexual maturity, wherein the recipient bird produces gametes derived from the donor PGCs. In one embodiment, the antigen comprises an epitope of a polypeptide selected from the group consisting of SSEA-1, VASA, EMA-1, germ cell-less, dead end, nanos, stella, fragilis, 5 and DAZL. In one embodiment, the recipient bird and the donor PGCs are each selected from the group consisting of chicken, turkey, duck, quail, sand hill crane, and whooping crane. In one embodiment, the donor PGCs are from the same avian species as the recipient bird. In another embodiment, the donor PGCs are from a different avian species as the recipient bird. In 10 one embodiment, the PGCs are selected from the group consisting of gonadal PGCs, blood PGCs, and germinal crescent PGCs.

In one embodiment of the instant method, the donor PGCs are administered when the recipient bird is between about stage IX according to the Eyal-Giladi & Kochav staging system and about stage 30 according to 15 the Hamburger & Hamilton staging system. In another embodiment, the donor PGCs are administered when the recipient bird is after stage 14 according to the Hamburger & Hamilton staging system. In another embodiment, the administering is by *in ovo* injection. In another embodiment, the administering step is carried out by injecting the recipient 20 bird with blastodermal cells, and wherein the blastodermal cells differentiate into donor PGCs in the recipient bird.

These and other aspects of the presently disclosed subject matter will become evident upon reference to the following detailed description and attached drawings. In addition, reference is made herein to various 25 publications. All of the patents (including published patent applications) and publications (including GENBANK® sequence references) that are cited herein are hereby incorporated by reference in their entireties to the same extent as if each were specifically stated to be incorporated by reference, to the extent that they supplement, explain, provide a background for or teach 30 methodology, techniques, and/or compositions employed herein. Any inconsistency between these patents and publications and the present

disclosure shall be resolved in favor of the present disclosure.

Brief Description of the Drawings

Figures 1-3 depict immunohistochemical analyses of the presence of SSEA-1⁺ cells in chicken embryos exposed to antibodies raised against 5 antigens associated with PGCs. For each Figure, cross sections of chicken embryos in the region of the developing gonads were stained using monoclonal antibody MC-480, which recognizes stage specific embryonic antigen-1 (SSEA-1) on primordial germ cells. Stage 27 embryos were fixed in 4% paraformaldehyde, paraffin sectioned at 7 µm, and immunostained 10 with MC-480 and an alkaline phosphatase-conjugated secondary antibody. Positive staining was detected with NBT-BCIP enzyme substrate.

Figure 4 is a bar graph that summarizes the results of examination of the sections described in Figures 1-3. Hens were immunized with the respective peptides and eggs were collected and incubated to reach 15 embryonic stage 27. Embryos were processed for routine histology, serially sectioned, and immunostained with monoclonal antibody MC-480 (anti-SSEA-1) to identify germ cells in the developing gonads. The data presented represent the average number of PGCs counted in 10 sections from the gonadal ridge of embryos in eggs from 3 immunized hens for each 20 peptide or combination of peptides.

Brief Description of the Sequence Listing

SEQ ID NOs: 1 and 2 are a nucleic acid and amino acid sequence, respectively, of a chicken VASA (CVH) open reading frame (GENBANK® Accession Nos. AB004836 and BAB12337, respectively).
25 SEQ ID NOs: 3 and 4 are the sequences of peptides comprising epitopes of a chicken VASA (CVH) polypeptide that were used to immunize female chickens. SEQ ID NO: 3 is an N-terminal peptide (Vasa-N) that corresponds to amino acids 42-57 of GENBANK® Accession No. BAB12337, and SEQ ID NO: 4 is a C-terminal peptide (Vasa-C) that 30 corresponds to amino acids 645-660 of GENBANK® Accession No. BAB12337.

SEQ ID NOs: 5 and 6 are a nucleic acid and amino acid sequence, respectively, of a chicken DAZL open reading frame (GENBANK® Accession Nos. AY211387 and AAO26019, respectively).

SEQ ID NOs: 7 and 8 are the sequences of peptides comprising 5 epitopes of a chicken DAZL polypeptide that were used to immunize female chickens. SEQ ID NO: 7 is an N-terminal peptide (Dazl-N) that corresponds to amino acids 2-18 of GENBANK® Accession No. AAO26019, and SEQ ID NO: 8 is a C-terminal peptide (DAZL-C) that corresponds to amino acids 266-282 of GENBANK® Accession No. AAO26019.

10

Detailed Description

I. Definitions

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the presently disclosed subject matter pertains. For 15 clarity of the present specification, certain definitions are presented hereinbelow.

Following long-standing patent law convention, the terms "a" and "an" mean "one or more" when used herein, including in the claims.

As used herein, the term "about", when referring to a value or to an 20 amount of mass, weight, time, volume, concentration or percentage is meant to encompass variations of $\pm 20\%$ or $\pm 10\%$, in another example $\pm 5\%$, in another example $\pm 1\%$, and in still another example $\pm 0.1\%$ from the specified amount, as such variations are appropriate to practice the presently disclosed subject matter. Unless otherwise indicated, all numbers 25 expressing quantities of ingredients, reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term "about". Accordingly, unless indicated to the contrary, the numerical parameters set forth in this specification and attached claims are approximations that can vary depending upon the desired properties 30 sought to be obtained by the presently disclosed subject matter.

In certain embodiments, the presently disclosed subject matter

employs antibodies against antigens associated with primordial germ cells. The term "antibody", and grammatical variations thereof, refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules; *i.e.*, molecules that contain an antigen-binding site that specifically bind an antigen. As such, the term refers to immunoglobulin proteins, or functional portions thereof, including polyclonal antibodies, monoclonal antibodies, chimeric antibodies, hybrid antibodies, single chain antibodies (*e.g.*, a single chain antibody represented in a phage library), mutagenized antibodies, humanized antibodies, and antibody fragments that comprise an antigen binding site (*e.g.*, Fab and Fv antibody fragments). Thus, "antibodies" include, but are not limited to monoclonal, chimeric, recombinant, synthetic, semi-synthetic, or chemically modified intact antibodies having for example Fv, Fab, scFv, or F(ab)₂ fragments. The immunoglobulin molecules of the presently disclosed subject matter can be of any type (*e.g.*, IgG, IgE, IgM, IgD, IgA and IgY), class (*e.g.*, IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2), or subclass of immunoglobulin molecule.

Avians produce antibodies that can localize in the yolk of eggs, and these antibodies are termed "IgY" (yolk antibodies, comprising mainly antibodies of the IgG type). See generally Bollen *et al.*, *J Immunol Meth* 20 191:113-120, 1996; Schade *et al.* (eds.), Chicken Egg Yolk Antibodies, Production and Application: IgY-Technology, Springer Verlag, New York, New York, United States of America, 2000. In one embodiment, the antibodies of the presently disclosed subject matter are avian IgY antibodies. The antibodies of the presently disclosed subject matter can be from any avian origin. In some embodiments, the antibodies are chicken IgY antibodies.

The antibodies of the presently disclosed subject matter bind to an antigen associated with primordial germ cells. As used herein, the term "associated with primordial germ cells" refers to a antigens comprising an epitope that is either expressed by, or post-translationally attached to, a polypeptide expressed by a primordial germ cell (for example, a cell surface

marker) or by a cell capable of influencing the migration and/or development of a primordial germ cell (for example, migration factors, growth factors, and polypeptides expressed by cells present in the microenvironment in which PGCs are present or develop). Such antigens include, but are not limited to 5 epitopes present on an SSAE-1, ovomucin-like protein (OLP), Steel Factor (c-kit ligand), germ cell-less, dead end, VASA (including, but not limited to the chicken VASA homolog, CVH), DAZL, nanos, stella, and fragilis polypeptides, and the antigens recognized by the antibodies EMA-1, QH-1, FC10.2, S-FC10.2, NC-1, 2C9, QCR1, AGC5, AGC7, and AGC13.

10 *Reviewed in* Tajima, *Avian Poultry Biol Rev* 13:15-20, 2002. *See also* Buehr, *Exp Cell Res* 232, 194-207, 1997; D'Costa & Petitte, *Intl J Devel Biol* 43:349-56, 1999; Urven *et al.*, *Development* 103:299-304, 1988; Hay *et al.*, *Cell* 55:577-587, 1988; Lasko & Ashburner, *Nature* 335:611-617, 1988; Raz, *Nature Genetics* 4:690-700, 2003; Houston & King, *Development* 127:447-15 56, 2000; Cooke *et al.*, *Hum Mol Genet* 5:513-516, 1996; Kimura *et al.*, *Biochem Biophys Res Commun* 262:223-30, 1999; Weidinger *et al.*, *Curr Biol* 13:1429-34, 2003; and references therein.

As used herein, the terms "SSEA-1 antibody" and "anti-SSEA-1 antibody" are used interchangeably and refer to an antibody, in one 20 embodiment an IgY antibody and in another embodiment a monoclonal antibody, which binds to the stage specific embryonic antigen-1 (SSEA-1; Buehr, *Exp Cell Res* 232, 194-207, 1997). SSEA-1 is a carbohydrate epitope determined by a galactose (β 1 \rightarrow 4)-fucose (α 1 \rightarrow 3) N-acetylglucosamine linkage (Gooi *et al.*, *Nature* 292:156-158, 1981). A 25 monoclonal antibody to SSEA-1 was developed by the fusion of mouse myeloma cells with spleen cells from a mouse that had been immunized with F9 teratocarcinoma cells (Solter & Knowles, *Proc Natl Acad Sci U S A* 75:5565-5569, 1978). SSEA-1 antibody is a known immunohistochemical marker for avian germ cells (Karagenc *et al.*, *Dev Genet* 19:290-301, 1996).

30 In one embodiment, an anti-SSEA-1 antibody is clone MC 480, which can be obtained from the Developmental Studies Hybridoma Bank, The University

of Iowa, Iowa City, Iowa, United States of America.

As used herein, the terms "VASA antibody" and "anti-VASA antibody" are used interchangeably and refer to an antibody, in one embodiment an IgY antibody, which binds to an avian VASA polypeptide. VASA is an ATP-dependent RNA helicases that is a member of the DEAD-box (Asp-Glu-Ala-Asp) family. VASA and its orthologs are expressed in the germplasm of many species, including zebrafish (*Danio rerio*), *Drosophila melanogaster*, *Caenorhabditis elegans*, and has been identified in PGCs from other species, including *Xenopus laevis*, the mouse, and humans (reviewed in Raz, *Nature Genetics* 4:690-700, 2003). In these species, VASA and related polypeptides have been implicated in germ cell development, including pole PGC development, proliferation, and differentiation, as well as gametogenesis. *Id.* The nucleic acid and amino acid sequences of chicken VASA (also called CVH) can be found at GENBANK® Accession Nos. AB004836 and BAB12337, respectively.

As used herein, the terms "DAZL antibody" and "anti-DAZL antibody" are used interchangeably and refer to an antibody, in one embodiment an IgY antibody, which binds to an avian DAZL polypeptide. Orthologs of DAZL have been isolated from several species, including zebrafish (*Danio rerio*), *Drosophila melanogaster*, *Caenorhabditis elegans*, and has been identified in PGCs from other species, including *Xenopus laevis*, the mouse, and humans (reviewed in Raz, *Nature Genetics* 4:690-700, 2003). The DAZL polypeptide (and orthologs thereof) is an RNA-binding protein that is expressed in the vegetal pole of the zebrafish egg and the germ plasm of *Xenopus*, as well as in the ovary and/or testis of several different organisms. *Id.* In *Xenopus*, mouse, and humans, DAZL is expressed in PGCs, and might be important for the development and survival of cells in the gonad of one or both sexes. See Raz, *Nature Genetics* 4:690-700, 2003; Xu *et al.*, *Proc Natl Acad Sci U S A* 98:7414-7419, 2001; Houston & King, *Development* 127:447-56, 2000; Mita & Yamashita, *Mech Dev* 94:251-255, 2000; Ruggiu *et al.*, *Nature* 389:73-77, 1997; Reijo *et al.*, *Nature Genetics*

10:383-393, 1995. The nucleic acid and amino acid sequences of chicken DAZL can be found at GENBANK® Accession Nos. AY211387 and AAO26019, respectively.

As used herein, the terms "bird" and "avian species" refer to any 5 avian species, including but not limited to chicken, turkey, duck, geese, quail, pheasant, and ostrich. Any of numerous other species can be employed to carry out the presently disclosed subject matter, particularly when it is used for the conservation of endangered species such as the whooping crane (where the recipient species would be the sand hill crane).

10 As used herein and unless specifically modified, the term "egg" refers to an avian egg that contains a live embryonic bird. Thus, the term "egg" is intended to refer to a fertilized avian egg, in one embodiment an egg containing an avian embryo that is capable of undergoing normal embryogenesis.

15 As used herein, the terms "native" and "endogenous" refer to a cell or a nucleic acid that is naturally present in the embryo. As such, an "endogenous PGC" is a PGC that is present in an embryo that has developed directed from the fertilized egg without the introduction of exogenous or donor PGCs. Similarly, when used in the context of a 20 polypeptide, a "native polypeptide" is a polypeptide that is encoded by a native gene of an untransformed avian.

As used herein, the term "naturally occurring" refers to an object that is found in nature as distinct from being artificially produced by man. For example, a polypeptide or nucleotide sequence that is present in an 25 organism (including a virus) in its natural state, which has not been intentionally modified or isolated by man in the laboratory, is naturally occurring. As such, a polypeptide or nucleotide sequence is considered "non-naturally occurring" if it is encoded by or present within a recombinant molecule, even if the amino acid or nucleic acid sequence is identical to an 30 amino acid or nucleic acid sequence found in nature.

As used herein, the terms "nucleic acid" and "nucleic acid molecule"

refer to any of deoxyribonucleic acid (DNA), ribonucleic acid (RNA), oligonucleotides, fragments generated by the polymerase chain reaction (PCR), and fragments generated by any of ligation, scission, endonuclease action, and exonuclease action.

5 The term "operatively linked", when describing the relationship between two nucleic acid regions, refers to a juxtaposition wherein the regions are in a relationship permitting them to function in their intended manner. For example, a control sequence "operatively linked" to a coding sequence is ligated in such a way that expression of the coding sequence is
10 achieved under conditions compatible with the control sequences, such as when the appropriate molecules (e.g., inducers and polymerases) are bound to the control or regulatory sequence(s). Thus, in one embodiment, the phrase "operatively linked" refers to a promoter connected to a coding sequence in such a way that the transcription of that coding sequence is
15 controlled and regulated by that promoter. Techniques for operatively linking a promoter to a coding sequence are well known in the art; the precise orientation and location relative to a coding sequence of interest is dependent, *inter alia*, upon the specific nature of the promoter.

Thus, the term "operatively linked" can refer to a promoter region that
20 is connected to a nucleotide sequence in such a way that the transcription of that nucleotide sequence is controlled and regulated by that promoter region. Similarly, a nucleotide sequence is said to be under the "transcriptional control" of a promoter to which it is operatively linked. Techniques for operatively linking a promoter region to a nucleotide
25 sequence are known in the art. The term "operatively linked" can also refer to a transcription termination sequence or other nucleic acid that is connected to a nucleotide sequence in such a way that termination of transcription of that nucleotide sequence is controlled by that transcription termination sequence. Additionally, the term "operatively linked" can refer to
30 a enhancer, silencer, or other nucleic acid regulatory sequence that when operatively linked to an open reading frame modulates the expression of that

open reading frame, either in a positive or negative fashion.

As used herein, the terms "polypeptide", "protein", and "peptide", which are used interchangeably herein, refer to a polymer of the 20 protein amino acids, or amino acid analogs, regardless of its size or function.

5 Although "protein" is often used in reference to relatively large polypeptides, and "peptide" is often used in reference to small polypeptides, usage of these terms in the art overlaps and varies. The term "polypeptide" as used herein refers to peptides, polypeptides and proteins, unless otherwise noted. As used herein, the terms "protein", "polypeptide" and "peptide" are used 10 interchangeably herein when referring to a gene product. The term "polypeptide" encompasses proteins of all functions, including enzymes. Thus, exemplary polypeptides include gene products, naturally occurring proteins, homologs, orthologs, paralogs, fragments, and other equivalents, variants and analogs of the foregoing.

15 As used herein, the terms "primordial germ cell" and "PGC" refer to a diploid cell that is present in the early embryo and that can differentiate/develop into haploid gametes (*i.e.* spermatozoa and ova) in an adult bird. Primordial germ cells can be isolated from different developmental stages and from various sites in a developing avian embryo 20 as is known to those of skill in the art including, but not limited to the genital ridge, the developing gonad, the blood, and the germinal crescent. See e.g. Chang *et al.*, *Cell Biol Int* 21:495-9, 1997; Chang *et al.*, *Cell Biol Int* 19:143-9, 1995; Allioli *et al.*, *Dev Biol* 165:30-7, 1994; Swift, *Am J Physiol* 15:483-516; and PCT International Publication No. WO 99/06533. The genital ridge 25 is a section of a developing embryo that is known to a person of ordinary skill in the art. See e.g., Strelchenko, *Theriogenology* 45: 130-141, 1996; Lavois, *J Reprod Dev* 37: 413-424, 1994. Typically, PGCS are stain positively in the periodic acid-Schiff (PAS) technique. In several species, PGCS can be identified using an anti-SSEA antibody (one notable exception being turkeys, 30 the PGCS from which do not display the SSEA antigen). Various techniques for isolation and purification of PGCS are known in the art, including the

concentration of PGCs from blood using Ficoll density gradient centrifugation (Yasuda et al., *J Reprod Fertil* 96:521-528, 1992).

The term “promoter” or “promoter region” each refers to a nucleotide sequence within a gene that is positioned 5' to a coding sequence and 5 functions to direct transcription of the coding sequence. The promoter region comprises a transcriptional start site, and can additionally include one or more transcriptional regulatory elements. In one embodiment, a method of the presently disclosed subject matter employs a RNA polymerase III promoter.

10 A “minimal promoter” is a nucleotide sequence that has the minimal elements required to enable basal level transcription to occur. As such, minimal promoters are not complete promoters but rather are subsequences of promoters that are capable of directing a basal level of transcription of a reporter construct in an experimental system. Minimal promoters include but 15 are not limited to the CMV minimal promoter, the HSV-tk minimal promoter, the simian virus 40 (SV40) minimal promoter, the human β -actin minimal promoter, the human EF2 minimal promoter, the adenovirus E1B minimal promoter, and the heat shock protein (hsp) 70 minimal promoter. Minimal promoters are often augmented with one or more transcriptional regulatory 20 elements to influence the transcription of an operatively linked gene. For example, cell-type-specific or tissue-specific transcriptional regulatory elements can be added to minimal promoters to create recombinant promoters that direct transcription of an operatively linked nucleotide sequence in a cell-type-specific or tissue-specific manner

25 Different promoters have different combinations of transcriptional regulatory elements. Whether or not a gene is expressed in a cell is dependent on a combination of the particular transcriptional regulatory elements that make up the gene's promoter and the different transcription factors that are present within the nucleus of the cell. As such, promoters 30 are often classified as “constitutive”, “tissue-specific”, “cell-type-specific”, or “inducible”, depending on their functional activities *in vivo* or *in vitro*. For

example, a constitutive promoter is one that is capable of directing transcription of a gene in a variety of cell types. Exemplary constitutive promoters include the promoters for the following genes which encode certain constitutive or "housekeeping" functions: hypoxanthine 5 phosphoribosyl transferase (HPRT), dihydrofolate reductase (DHFR; Scharfmann et al., 1991), adenosine deaminase, phosphoglycerate kinase (PGK), pyruvate kinase, phosphoglycerate mutase, the β -actin promoter (see e.g., Williams et al., 1993), and other constitutive promoters known to those of skill in the art. "Tissue-specific" or "cell-type-specific" promoters, on 10 the other hand, direct transcription in some tissues and cell types but are inactive in others. Exemplary tissue-specific promoters include those promoters described in more detail hereinbelow, as well as other tissue-specific and cell-type specific promoters known to those of skill in the art.

When used in the context of a promoter, the term "linked" as used 15 herein refers to a physical proximity of promoter elements such that they function together to direct transcription of an operatively linked nucleotide sequence

The term "transcriptional regulatory sequence" or "transcriptional regulatory element", as used herein, each refers to a nucleotide sequence 20 within the promoter region that enables responsiveness to a regulatory transcription factor. Responsiveness can encompass a decrease or an increase in transcriptional output and is mediated by binding of the transcription factor to the DNA molecule comprising the transcriptional regulatory element. In one embodiment, a transcriptional regulatory 25 sequence is a transcription termination sequence, alternatively referred to herein as a transcription termination signal.

As used herein, "significance" or "significant" relates to a statistical analysis of the probability that there is a non-random association between two or more entities. To determine whether or not a relationship is 30 "significant" or has "significance", statistical manipulations of the data can be performed to calculate a probability, expressed as a "p-value". Those p-

values that fall below a user-defined cutoff point are regarded as significant. In one example, a p-value less than or equal to 0.05, in another example less than 0.01, in another example less than 0.005, and in yet another example less than 0.001, are regarded as significant.

5 The term "regulatory sequence" is a generic term used throughout the specification to refer to polynucleotide sequences, such as initiation signals, enhancers, regulators, promoters, and termination sequences, which are necessary or desirable to affect the expression of coding and non-coding sequences to which they are operatively linked. Exemplary regulatory
10 sequences are described in Goeddel, 1990, and include, for example, the early and late promoters of simian virus 40 (SV40), adenovirus or cytomegalovirus immediate early promoter, the lac system, the trp system, the TAC or TRC system, T7 promoter whose expression is directed by T7 RNA polymerase, the major operator and promoter regions of phage
15 lambda, the control regions for fd coat protein, the promoter for 3-phosphoglycerate kinase or other glycolytic enzymes, the promoters of acid phosphatase, e.g., Pho5, the promoters of the yeast a-mating factors, the polyhedron promoter of the baculovirus system and other sequences known to control the expression of genes of prokaryotic or eukaryotic cells or their
20 viruses, and various combinations thereof. The nature and use of such control sequences can differ depending upon the host organism. In prokaryotes, such regulatory sequences generally include promoter, ribosomal binding site, and transcription termination sequences. The term "regulatory sequence" is intended to include, at a minimum, components
25 whose presence can influence expression, and can also include additional components whose presence is advantageous, for example, leader sequences and fusion partner sequences.

 In certain embodiments, transcription of a polynucleotide sequence is under the control of a promoter sequence (or other regulatory sequence) that
30 controls the expression of the polynucleotide in a cell-type in which expression is intended. It will also be understood that the polynucleotide can

be under the control of regulatory sequences that are the same or different from those sequences which control expression of the naturally occurring form of the polynucleotide.

The term "reporter gene" refers to a nucleic acid comprising a
5 nucleotide sequence encoding a protein that is readily detectable either by its presence or activity, including, but not limited to, luciferase, fluorescent protein (e.g., green fluorescent protein), chloramphenicol acetyl transferase, β -galactosidase, secreted placental alkaline phosphatase, β -lactamase, human growth hormone, and other secreted enzyme reporters. Generally, a
10 reporter gene encodes a polypeptide not otherwise produced by the host cell, which is detectable by analysis of the cell(s), e.g., by the direct fluorometric, radioisotopic or spectrophotometric analysis of the cell(s) and typically without the need to kill the cells for signal analysis. In certain instances, a reporter gene encodes an enzyme, which produces a change in
15 fluorometric properties of the host cell, which is detectable by qualitative, quantitative, or semiquantitative function or transcriptional activation. Exemplary enzymes include esterases, β -lactamase, phosphatases, peroxidases, proteases (tissue plasminogen activator or urokinase) and other enzymes whose function can be detected by appropriate chromogenic
20 or fluorogenic substrates known to those skilled in the art or developed in the future.

As used herein, the term "transcription factor" refers to a cytoplasmic or nuclear protein which binds to a gene, or binds to an RNA transcript of a gene, or binds to another protein which binds to a gene or an RNA transcript
25 or another protein which in turn binds to a gene or an RNA transcript, so as to thereby modulate expression of the gene. Such modulation can additionally be achieved by other mechanisms; the essence of a "transcription factor for a gene" pertains to a factor that alters the level of transcription of the gene in some way. The term "transcription factor" can
30 also generally refer to a protein that modulates gene expression by interaction with the transcriptional regulatory element and cellular

components for transcription, including RNA Polymerase, Transcription Associated Factors (TAFs), chromatin-remodeling proteins, and any other relevant protein that impacts gene transcription.

The term "vector" refers to a nucleic acid capable of transporting
5 another nucleic acid to which it has been linked. One type of vector that can
be used in accord with the presently disclosed subject matter is an episome,
i.e., a nucleic acid capable of extra-chromosomal replication. Other vectors
include those capable of autonomous replication and expression of nucleic
acids to which they are linked. Vectors capable of directing the expression
10 of genes to which they are operatively linked are referred to herein as
"expression vectors". In general, expression vectors of utility in recombinant
DNA techniques are often in the form of plasmids. In the present
specification, "plasmid" and "vector" are used interchangeably as the plasmid
is the most commonly used form of vector. However, the presently disclosed
15 subject matter is intended to include such other forms of expression vectors
which serve equivalent functions and which become known in the art
subsequently hereto.

The term "expression vector" as used herein refers to a DNA
sequence capable of directing expression of a particular nucleotide
20 sequence in an appropriate host cell, comprising a promoter operatively
linked to the nucleotide sequence of interest which is operatively linked to
transcription termination sequences. It also typically comprises sequences
required for proper translation of the nucleotide sequence. The construct
comprising the nucleotide sequence of interest can be chimeric. The
25 construct can also be one that is naturally occurring but has been obtained
in a recombinant form useful for heterologous expression. The nucleotide
sequence of interest, including any additional sequences designed to effect
proper expression of the nucleotide sequences, can also be referred to as
an "expression cassette".

30 The terms "heterologous gene", "heterologous DNA sequence",
"heterologous nucleotide sequence", "exogenous nucleic acid molecule", or

"exogenous DNA segment", as used herein, each refer to a sequence that originates from a source foreign to an intended host cell or, if from the same source, is modified from its original form. Thus, a heterologous gene in a host cell includes a gene that is endogenous to the particular host cell but 5 has been modified, for example by mutagenesis or by isolation from native transcriptional regulatory sequences. The terms also include non-naturally occurring multiple copies of a naturally occurring nucleotide sequence. Thus, the terms refer to a DNA segment that is foreign or heterologous to the cell, or homologous to the cell but in a position within the host cell nucleic 10 acid wherein the element is not ordinarily found.

Two nucleic acids are "recombined" when sequences from each of the two nucleic acids are combined in a progeny nucleic acid. Two sequences are "directly" recombined when both of the nucleic acids are substrates for recombination. Two sequences are "indirectly recombined" 15 when the sequences are recombined using an intermediate such as a cross over oligonucleotide. For indirect recombination, no more than one of the sequences is an actual substrate for recombination, and in some cases, neither sequence is a substrate for recombination.

As used herein, the term "regulatory elements" refers to nucleotide 20 sequences involved in controlling the expression of a nucleotide sequence. Regulatory elements can comprise a promoter operatively linked to the nucleotide sequence of interest and termination signals. Regulatory sequences also include enhancers and silencers. They also typically encompass sequences required for proper translation of the nucleotide 25 sequence.

As used herein, the term "significant increase" refers to an increase in an amount (for example, a number of PGCs) that is larger than the margin of error inherent in the measurement technique, in one embodiment an increase by about 10% or greater over a baseline amount (for example, the 30 average number of PGCs present at a specific location at a specific stage of development in an untreated, wild-type embryo), in another embodiment an

increase by about 25% or greater, and in still another embodiment an increase by about 50% or greater.

As used herein, the terms "significantly less" and "significantly reduced" refer to an amount (for example, a number of PGCs) that is 5 reduced by more than the margin of error inherent in the measurement technique, in one embodiment a decrease by about 10% or greater with respect to a baseline amount (for example, the average number of PGCs present at a specific location at a specific stage of development in an untreated, wild-type embryo), in another embodiment, a decrease by about 10 25% or greater, and in still another embodiment a decrease by about 50% or greater.

As used herein, the term "specific binding", and grammatical variants thereof, refers to an affinity of binding that an antibody has to a cognate epitope. With respect to the disclosed methods, "specific binding" is 15 intended to encompass a binding between an antibody (for example, an IgY molecule) and an antigen under physiological conditions (for example, within a location wherein PGCs can be found in an avian embryo) that results in a modulation of the normal biological activity of the macromolecule comprising the epitope. Stated another way, in one embodiment, an interaction 20 between an IgY molecule and an epitope is considered specific if a biological activity of the macromolecule to which the IgY molecule binds in a developing embryo is altered relative to the activity of the macromolecule in another developing embryo at a similar stage in the absence of the IgY molecule.

25 As such, the phrases "specifically (or selectively) binds to an antibody" and "specifically immunoreactive with", when referring to an epitope present on a polypeptide or peptide, refer to a binding reaction which is determinative of the presence of the polypeptide in the presence of a heterogeneous population of polypeptides and other biologics. Thus, under 30 designated immunoassay conditions, the specified antibodies bind to a particular polypeptide and do not bind in a significant amount to other

polypeptides present in the sample. Specific binding to an antibody under such conditions can require an antibody that is selected for its specificity for a particular polypeptide. For example, antibodies raised to an antigen associated with PGCs can be selected to obtain antibodies specifically immunoreactive with that antigen and not with other antigens. A variety of immunoassay formats can be used to select antibodies specifically immunoreactive with a particular polypeptide. For example, solid phase ELISA immunoassays, Western blots, or immunohistochemistry are routinely used to select monoclonal antibodies specifically immunoreactive with a polypeptide. See Harlow & Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratories, Cold Spring Harbor, New York, United States of America, 1988, for a description of immunoassay formats and conditions that can be used to determine specific immunoreactivity. Typically a specific or selective reaction will be at least twice background signal or noise and more typically more than 10 to 100 times background.

As used herein, the term "transformation" refers to a process for introducing heterologous DNA into an avian cell, avian tissue, or avian. Transformed avian cells, avian tissue, and avians are understood to encompass not only the end product of a transformation process, but also transgenic progeny thereof.

As used herein, the terms "transformed", "transgenic", and "recombinant" refer to a host organism such as an avian PGC into which a heterologous nucleic acid molecule has been introduced. The nucleic acid molecule can be stably integrated into the genome of the host or the nucleic acid molecule can also be present as an extrachromosomal molecule. Such an extrachromosomal molecule can be auto-replicating. Transformed cells, tissues, or cells are understood to encompass not only the end product of a transformation process, but also transgenic progeny thereof. A "non-transformed," "non-transgenic", or "non-recombinant" host refers to a wild-type organism, e.g., a wild-type avian PGC, which does not contain the heterologous nucleic acid molecule.

II. Immunizing Birds and the Deposition of Antibodies in Egg Yolk

Avians, in particular chickens, have become an increasingly common source of large-scale production of polyclonal antibodies due to the fact that large amounts of antibodies are transferred from serum to the yolk of eggs 5 during egg production. See Rose *et al.*, *Eur J Immunol* 4:521, 1974. The presently disclosed subject matter takes advantage of this phenomenon to effect PGC development in embryos by immunizing female avians with antigens associated with PGCs, which collect in the yolk. These antibodies can then bind to their cognate antigens during avian embryogenesis, thereby 10 affecting the biological activities of polypeptides associated with PGC development.

A. Antigens and Epitopes

The presently disclosed subject matter encompasses polypeptides comprising, or alternatively consisting of, epitopes of the polypeptide that 15 can be used to generate IgY antibodies that bind to the epitopes. In alternative, non-limiting embodiments, the polypeptides comprise an amino acid sequence of SEQ ID NOs: 2 or 6, and the epitopes are present on peptide antigens having an amino acid sequence of SEQ ID NOs: 3, 4, 7, or 8. It should be noted, however, that the peptide antigens disclosed herein 20 as Vasa-N, Vasa-C, Dazl-N, and Dazl-C are intended to be representative only, and other antigenic peptides and polypeptides, including the full length version of a polypeptide associated with PGC development (including, but not limited to a polypeptide comprising an amino acid sequence presented in SEQ ID NOs: 2 or 6) can be used as immunogens.

25 The term "epitopes", as used herein, refers to portions of a polypeptide that have antigenic or immunogenic activity in an avian, in one embodiment a chicken. In one embodiment, the presently disclosed subject matter encompasses a polypeptide comprising an epitope, as well as the polynucleotide encoding this polypeptide. An "immunogenic epitope", as 30 used herein, is defined as a portion of a protein that elicits an antibody response in an avian, as determined by any method known in the art, for

example, by the methods for generating antibodies described herein. The term "antigenic epitope," as used herein, is defined as a portion of a protein to which an antibody can immunospecifically bind its antigen as determined by any method well known in the art, for example, by the immunoassays 5 described herein. Immunospecific binding excludes non-specific binding but does not necessarily exclude cross-reactivity with other antigens. Antigenic epitopes need not necessarily be immunogenic. It is to be understood that as used herein, the term epitope encompasses any portion of a polypeptide that has antigenic or immunogenic activity in an avian including, but not 10 limited to a subset of the amino acids of the polypeptide itself (also referred to herein as a "peptide antigen"), but also including any modifications of the polypeptide that incorporate additional moieties into the polypeptide (for example, the post-translational addition of one or more carbohydrate groups).

15 Fragments that function as epitopes can be produced by any conventional approach. See e.g., Houghten, *Proc Natl Acad Sci U S A* 82:5131-5135, 1985; further described in U.S. Patent No. 4,631,211.

In the presently disclosed subject matter, antigenic epitopes contain a sequence of in one embodiment at least 4, in another embodiment at least 5, 20 in another embodiment at least 6, in another embodiment at least 7, in another embodiment at least 8, in another embodiment at least 9, in another embodiment at least 10, in another embodiment at least 15, in another embodiment at least 20, in another embodiment at least 25, and in still another embodiment between about 15 to about 30 amino acids. 25 Representative polypeptides comprising immunogenic or antigenic epitopes are at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 amino acid residues in length. Antigenic epitopes are useful, for example, to raise antibodies, including IgY antibodies, which specifically bind the epitope. Antigenic epitopes can be used as the target molecules in 30 immunoassays. See e.g., Wilson *et al.*, *Cell* 37:767-778, 1984; Sutcliffe *et al.*, *Science* 219:660-666, 1983.

Similarly, immunogenic epitopes can be used, for example, to induce antibodies according to methods well known in the art. See e.g., Sutcliffe et al., *supra*; Wilson et al., *supra*; Chow et al., *Proc Natl Acad Sci U S A* 82:910-914, 1985; and Bittle et al., *J Gen Virol* 66:2347-2354, 1985. The 5 polypeptides comprising one or more immunogenic epitopes can be presented for eliciting an antibody response together with a carrier protein, such as an albumin, to an avian system (such as, for example, chicken), or, if the polypeptide is of sufficient length (at least about 25 amino acids), the polypeptide can be presented without a carrier. However, immunogenic 10 epitopes comprising as few as 8 to 10 amino acids have been shown to be sufficient to raise antibodies capable of binding to, at the very least, linear epitopes in a denatured polypeptide (e.g., in Western blotting).

Epitope-bearing polypeptides of the presently disclosed subject matter can be used to induce antibodies according to methods well known in 15 the art including, but not limited to, in vivo immunization. See e.g., Sutcliffe et al., *supra*; Wilson et al., *supra*; and Bittle et al., *supra*. If in vivo immunization is used, avians can be immunized with free peptide; however, anti-peptide antibody titer may be boosted by coupling the peptide to a macromolecular carrier, such as keyhole limpet hemacyanin (KLH), bovine 20 serum albumin (BSA), or tetanus toxoid. For instance, peptides containing cysteine residues can be coupled to a carrier using a linker such as maleimidobenzoyl-N-hydroxysuccinimide ester (MBS), while other peptides can be coupled to carriers using a more general linking agent such as glutaraldehyde. Avians such as, for example, chickens, are immunized with 25 either free or carrier-coupled peptides, for instance, by intramuscular injection (for example, into the pectoralis major) of emulsions containing about 10-1000 micrograms of peptide or carrier protein and Freund's adjuvant or any other adjuvant known for stimulating an immune response. Several booster injections can be employed, for instance, at intervals of 30 about two weeks, to provide a useful titer of anti-peptide antibody that can be detected, for example, by ELISA assay using free peptide adsorbed to a

solid surface. The titer of anti-peptide antibodies in serum from an immunized animal can be increased by selection of anti-peptide antibodies, for instance, by adsorption to the peptide on a solid support and elution of the selected antibodies according to methods well known in the art.

5 **B. Conjugates and Adjuvants**

As is well known in the art, a given composition may vary in its immunogenicity. It is often necessary therefore to boost the host immune system, as may be achieved by conjugating a peptide or polypeptide immunogen to a carrier. Representative carriers are keyhole limpet 10 hemocyanin (KLH) and bovine serum albumin (BSA). Other albumins such as ovalbumin, mouse serum albumin, or rabbit serum albumin can also be used as carriers. Methods for conjugating a polypeptide to a carrier protein are well known in the art and include the use of glutaraldehyde, m-maleimidobenzoyl-N-hydroxysuccinimide ester, carbodiimide, and bis-15 biazotized benzidine.

As is also well known in the art, the immunogenicity of a particular immunogen composition can be enhanced by the use of non-specific stimulators of the immune response, known as adjuvants. Representative adjuvants include complete Freund's adjuvant (a non-specific stimulator of 20 the immune response containing killed *Mycobacterium tuberculosis*), incomplete Freund's adjuvant, aluminum hydroxide, and TITERMAX® adjuvant (TMA; CytRx Corp., Norcross, Georgia, United States of America).

The amount of immunogen composition used in the production of polyclonal antibodies varies upon the nature of the immunogen as well as 25 the animal used for immunization. A variety of routes can be used to administer the immunogen (subcutaneous, intramuscular, intravenous and intraperitoneal). In one embodiment, avians are immunized by intramuscular injection of an antigen preparation into the pectoralis major muscle. The production of polyclonal antibodies can be monitored by sampling blood of 30 the immunized animal at various points following immunization. Subsequent, booster injections can also be given. The process of boosting

and titering is repeated until a suitable titer is achieved. When a desired level of immunogenicity is obtained, the immunized animal can be bled and the serum isolated and stored.

C. Isolation of Antibodies from Yolk

5 Antibodies that bind to antigens associated with PGCs are deposited in the yolk of eggs produced by female birds immunized with the antigens (for example, with peptides comprising the antigens). In some embodiments, antibodies can be isolated from the yolk using techniques known to those of skill in the art. See e.g. Akita *et al.*, *J Immunol Meth* 10 160:207-214, 1993; Akita *et al.*, *J Food Sci* 57:629-634, 1992; U.S. Patent No. 4,357,272. As taught in U.S. Patent No. 4,357,272, IgY can be purified from yolk by precipitation with polyethylene glycol (PEG). Briefly, yolks can be collected and washed in distilled water to remove albumen. Yolks can be passed through a glass funnel into a measuring cylinder, which causes the 15 yolk sacs to break and releases the yolk, which collects in the cylinder. The volume of yolk is measured and a volume of buffer (for example, phosphate buffered saline; PBS) equivalent to two volumes of yolk is added and thoroughly mixed. PEG (for example, PEG 6000) is added to a final concentration of 3.5% (weight:volume; w:v). The mixture is stirred until the 20 PEG is completely dissolved. The mixture is then centrifuged at 12,000g for ten minutes. The centrifugation step results in the production of three phases in the centrifuge tubes. The top layer is a yellow fatty layer, the middle layer is a clear supernatant layer, and a bottom layer consisting of the bulk of the yolk and a protein "pellet". The IgY-containing supernatant fluid and the fatty 25 layer can be decanted into a funnel containing an absorbent cotton plug in the neck of the funnel. The plug removes the lipid layer. The volume of the clear filtrate is then measured and PEG added by gentle stirring to a final concentration of 12 g PEG per 100 ml yolk extract. At this concentration the PEG causes complete displacement of the IgY. The precipitate is then 30 centrifuged as before. The pellets can be redissolved to the original volume in phosphate buffer and the IgY once more precipitated with 12% PEG and

centrifuged. Residual PEG can be removed by two rounds of re-centrifugation and aspiration of any liquid (IgY being found in the pellet). Thereafter, the final pellets can be dissolved in a volume of phosphate buffer equivalent to half the volume of yolk from which it was derived, although by 5 dissolving the pellets in a smaller volume, more concentrated solutions can be obtained if desired. For injection into animals where a more complete removal of PEG is desirable, the IgY can be freed of traces of PEG by precipitation of the IgY with half saturated ammonium sulfate followed by centrifugation. The PEG forms a liquid phase in the aqueous ammonium 10 sulfate phase, while the IgY forms a third phase on the bottom of the centrifuge tube.

IgY purified by this, or any other method known to those in the art, can be used in immunoassays including, but not limited to enzyme-linked immunosorbent assays (ELISAs), immunoprecipitation, etc., using 15 techniques that are known in the art. Standard secondary reagents, such as anti-IgY secondary antibodies, are available from a number of manufacturers, including Research Diagnostics Inc., Flanders, New Jersey, United States of America, and Aves Labs, Inc., Tigard, Oregon, United States of America.

20 **III. Methods of Modulating PGC Proliferation and Development**

The presently disclosed subject matter provides methods for modulating PGC development in an avian embryo. The modulation provided by the disclosed methods can take the form of either a qualitative or quantitative difference in the PGCs of the embryo, including but not limited to 25 a reduction or an enhancement of the number of PGCs present in the developing embryo relative to the number of PGCs normally found in a same stage embryo of the same species that has not been exposed to the methods described herein. Alternatively, the modulation can take the form of interference with the normal development of PGCs in the embryo such that 30 the PGCs fail to develop normally, either in terms of migration to the gonad or in terms of their development once they enter the microenvironment of the

embryonic gonad.

Several groups have reported the use of chemicals or radiation to modulate the level of PGCs in avian embryos. One particular chemical that has been used to reduce endogenous PGCs levels is busulfan (see Aige-Gil & Simkiss, *Res Vet Sci* 50:139, 1991; Vick et al., *J Reprod Fert* 98:637; Bresler et al., *Br Poutry Sci* 35:241, 1994; Hallett & Wentworth, *Poultr Sci* 70:1619, 1991; U.S. Patent Application Publication No. 20030111016). The compound busulfan (1,4-butanediol dimethane sulfonate, BU) has been used as a chemotherapeutic agent in the treatment of leukemia (Bhagwatwar et al., *Cancer, Chemother Pharmacol* 37:401-08, 1996). In 1963, Hemsworth and Jackson demonstrated that the administration of BU in rats could markedly impair the development of PGCs (Hemsworth & Jackson, *J Reprod Dev* 6:229-33, 1963). Injection of BU into the yolk sac of chick embryos resulted in multiple malformations (Swartz, *Teratology* 21:1-8, 1980). Hallett and Wentworth (*Poult Sci* 70:1619-23, 1991) also reported significant declines in hatchability following injection of an albumen suspension of BU into quail eggs. In some BU treated quail, there appeared to be an absence of germ cells in the gonads, while other similarly treated birds appeared normal. The authors suggested that "inconsistencies in the delivery of BU to the embryo" might explain the observed variation. They concluded that discovering a non-toxic solvent system would be necessary to eliminate the inconsistent results associated with use of a suspension. Aige-Gil & Simkiss (*Br Poult Sci* 32:427-438, 1991) used saline or sesame oil suspensions of BU, or solublized BU in dimethyl sulphoxide (DMSO) in chick embryos. Administration of DMSO alone produced embryonic mortality, developmental delays, and malformations that exceeded those observed with saline. The teratogenic effects were greatly minimized when BU was suspended in sesame oil and injected into yolk. Injection of 100 µg BU in sesame oil resulted in a sterility index of 95+%. In a subsequent experiment, Vick and co-workers (*J Reprod Fertil* 98:637-41, 1993) reported that the injection of 25, 50, and 250 µg BU significantly reduced gonadal

germ cells in chick embryos. They estimated that BU treatment increased the rate of germline chimerism 3.5-fold when compared to non-BU treated embryos. Bresler *et al.* (*Br Poult Sci* 35:241-47, 1994) demonstrated that treatment with BU and subsequent injection of PGCs could result in a 5 significant repopulation of the gonad. Injection of 50 µg BU, suspended in sesame oil reduced PGCs in the left and right gonad of 6 day-old chick embryos by 75 and 78%, respectively. Following the injection of a suspension of germinal crescent cells into BU-treated embryos, PGC numbers increased to 72 and 115% of controls for the left and right gonad, 10 respectively. The variability in delivery of BU to the gonad, and the resulting inconsistency in the effectiveness in reducing the number of PGCs, limits the usefulness of this technology.

In U.S. Patent Application Publication No. 20030111016, the present co-inventors used of busulfan to reduce endogenous PGCs prior to 15 administering donor PGCs. Briefly, fifteen mg of busulfan was dissolved in 5 ml of dimethyl formamide (DMF) in a glass vial. Five ml of sesame oil was added to the solution. The mixture was vortexed completely to create an emulsion. The concentration of busulfan was 1.5 µg/µl in the emulsion. Fresh busulfan emulsion was prepared for each batch of injections. 20 Fertilized eggs were incubated at 37.5°C, 60% relative humidity for 22 hours. Then the eggs were placed horizontally in the incubator for 2 hours. The blunt end of each egg was cleaned with 70% ethanol. Using a curved forceps, a small hole was then made in the shell covering the air chamber, without damaging the outer shell membrane. Fifty µl of busulfan emulsion 25 (containing 75 µg busulfan) was injected horizontally through the air chamber into the yolk using a hypodermic needle (21G x 1.5 inch). The emulsion was vortexed completely before use. The eggs were kept horizontal for the entire injection procedure. The hole in the shell was sealed with scotch tape. The eggs were incubated vertically after injection.

30 Busulfan-treated embryos were collected at stage 27 (H&H) and fixed in 4% paraformaldehyde. The embryos were embedded in paraffin,

sectioned at 7 μm thickness, and stained immunohistochemically with SSEA-1 antibody. The number of PGCs in the left and right gonad in 10 randomly selected sections from each embryo was counted, and the index of sterility (IS) was calculated using the equation IS = (N--X)/N where N is the
5 PGC number from control gonads and X is the PGC number from busulfan treated embryo (Reynaud, *J Embryol Exp Morphol* 21:485-507, 1969). The effects of treatment with sesame oil, DMF, and busulfan on survivability of chick embryos to Stage 27 was determined, and hatchability of treated birds following administration of busulfan was also assessed. Busulfan was
10 shown to reduce PGCs numbers, particularly at a dose of 75 μg emulsified in sesame oil and DMF, although survivability of the treated embryos was one-quarter to one-half that seen in uninjected controls.

In some embodiments, the presently disclosed subject matter provides a method for modulating primordial germ cells numbers in an avian
15 embryo, the method comprising immunizing a female bird with an antigen associated with primordial germ cells, whereby an egg produced by the female bird comprises a sufficiently high concentration of antibodies specific for the antigen to modulate numbers of endogenous PGCs in an avian embryo present within in the egg.

20 As used herein, the term "modulate" refers to an increase, decrease, or other alteration of any, or all, chemical and biological activities or properties of a biochemical entity, e.g., a PGC. As such, the term "modulate" can refer to a change in the numbers of PGCs present in the developing embryo relative to non-chimeric embryos of the same species at
25 the same stage. For example, the term "modulate" can mean "inhibit", "reduce", or "suppress", but the use of the word "modulate" is not limited to this definition.

As used herein, the terms "inhibit", "reduce", "suppress", "down regulate", and grammatical variants thereof are used interchangeably and
30 refer to an activity whereby the number or development of PGCs present in an embryo is reduced below that observed in the absence of antibodies

directed against an antigen present on a polypeptide associated with PGCs. In one embodiment, inhibition with an antibody molecule (for example, an IgY directed against VASA, DAZL, EMA-1, etc.) results in a decrease in the number of PGCs present in the embryo prior to repopulation with donor
5 PGCs.

In another embodiment, the number of PGCs present in an avian embryo is greater in the presence of antibodies directed against an antigen present on a polypeptide associated with PGCs than in their absence.

The term "modulation" as used herein refers to both upregulation (*i.e.*,
10 activation, enhancement, or stimulation) and downregulation (*i.e.*, inhibition, reduction, or suppression) of the number of PGCs (or the development thereof) in the embryo prior to repopulation with donor PGCs. Thus, the term "modulation", when used in reference to a functional property or biological activity or process (*e.g.*, the development, including but not limited
15 to the proliferation, of PGCs) refers to the capacity to upregulate (*e.g.*, activate, enhance, or stimulate), downregulate (*e.g.*, inhibit, reduce, or suppress), or otherwise change a quality of such property, activity, or process (for example, PGC development and proliferation).

In particular embodiments of the presently disclosed subject matter,
20 the number of endogenous PGCs in the recipient bird is reduced prior to introduction of the donor PGCs. In this manner, the donor PGCs can repopulate the gonads of the recipient bird and can increase the efficiency of producing chimeric birds and the proportion of gametes (and offspring) that are derived from the donor bird. The endogenous PGCs can be reduced by
25 at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98% or even more. In other particular embodiments, the recipient bird is essentially sterilized, as that term is defined herein. The targeted reduction in endogenous PGC number in the recipient bird can be based on a number of considerations, including, but not limited to the desired number and
30 proportion of gametes to be derived from the donor bird, minimization of any adverse effects associated with the method of achieving endogenous PGC

reduction, and the like.

Alternatively stated, the presently disclosed methods can be practiced so that the ratio of gametes (and/or offspring) derived from the donor PGCs as compared with the recipient bird's PGCs may be about 10/90, 20/80, 5 30/70, 40/60, 50/50, 60/40, 70/30, 80/20, 90/10, or higher. In some embodiments, the methods of the presently disclosed subject matter can be practiced so that fewer than 50% of the gametes (and/or offspring) are derived from the donor PGCs. A relatively low proportion of gametes and/or offspring derived from donor PGCs can be acceptable in those applications 10 in which only a relatively small number of donor gametes and/or offspring from chimeric birds are necessary and/or the donor gametes and/or offspring from chimeric birds are commercially valuable.

In one embodiment, PGC numbers in the recipient bird are reduced as a result of the presence of maternal antibodies deposited in the yolk of 15 the egg. These antibodies, generally referred to as IgY, are capable of influencing the development of PGCs in the embryo when they bind to antigens present on polypeptides associated with PGCs, in one embodiment antigens that are present on polypeptides that are associated with PGC migration or development.

20 The reduction in PGCs is achieved by immunizing a female bird with an antigen associated with PGCs. The antigen can be present on a polypeptide associated with PGCs development (for example, a VASA polypeptide), including but not limited to a peptide antigen (for example, a stretch of 4 or more amino acids of a VASA polypeptide) and a carbohydrate 25 antigen (for example, a carbohydrate moiety post-translationally added to polypeptide on the surface of a PGC). When a female bird is immunized with such an antigen (or a plurality of antigens), the bird can generate an immune response to the antigen. When an immunized bird produces an egg, antibodies to the antigen are deposited into the yolk of the egg. Those 30 antibodies are then capable of binding to their cognate antigens present in the embryo developing in the egg, thereby modulating a biological activity of

macromolecules present within the developing embryo that contain the antigen.

IV. Methods of Producing Chimeric Avians

The presently disclosed subject matter also provides a method for
5 producing a chimeric avian. In some embodiments, the method comprises
(a) immunizing a female avian with an antigen associated with primordial
germ cells; (b) producing an egg from the female bird, wherein the egg
comprises a sufficiently high concentration of antibodies specific for the
antigen to modulate PGC development, PGC numbers, or combinations
10 thereof, in a recipient embryo present within the egg; and (c) administering
donor PGCs to the recipient embryo *in ovo* to produce a chimeric avian.

Chimeric avians have been produced by transferring donor
blastodermal cells into a recipient avian blastoderm. *Reviewed in Etches et*
al., Poult Sci 76:1075, 1997. Chimeric avians, particularly germ line
15 chimeras, have also been produced by transfer of PGCs into recipient
embryos, including PGCs derived from germinal crescent, circulating PGCs
found in blood, and gonadal PGCs found in the genital ridge. *Reviewed in*
Tajima, Avian Poult Biol Rev 13:15-30, 2002. It has been reported that
blastodermal cells contain presumptive PGCs (Kagami *et al.*, *Mol Reprod*
20 *Dev* 48:501, 1997; Ginsburg & Eyal-Giladi, *J Embryol Exp Morphol* 95:53,
1986), which if true might explain the ability to generate germ line chimeric
avians by blastodermal cell transfer. In some embodiments of the presently
disclosed subject matter, blastodermal cells and/or PGCs can be introduced
into developing avian embryos by techniques that are known in the art,
25 including injection of cells into the sinus terminalis, injection into the
aorta, injection into the germinal crescent, injection into the embryonic
coelom, etc.

The majority of avian chimera production has employed the chicken.
See e.g. Naito *et al.*, *Mol Reprod Dev* 39:153-161, 1994. The production of
30 chimeric avians is not limited to chickens, however. Chimeras have also
been produced in quail by transferring early blastodermal cells from the quail

into quail embryos. See Ono *et al.*, *Jpn Poult Sci* 31:119, 1994. Additionally, inter-specific chimeras have been produced by introducing quail blastodermal cells into the chicken blastoderm (Watanabe *et al.*, *Development* 114:331-338, 1992) and by introducing dissociated turkey 5 germinal crescent cells and/or PGCs into chick embryos (Reynaud, *J Exbryol Exp Morphol* 21:485-507, 1969; U.S. Patent No. 6,354,242; U.S. Patent Application Publication 20030111016).

Those skilled in the art will appreciate that the donor PGCs can be genetically modified prior to administration to the recipient bird, for example, 10 by gene disruption and/or to introduce one or more heterologous nucleotide sequence(s). Methods of transiently or stably introducing a heterologous sequence into avian cells are known in the art (see e.g., U.S. Patent No. 5,162,215 to Bosslman et al.). In one embodiment, the heterologous nucleotide sequence is stably incorporated into the PGC. Approaches for 15 introducing nucleic acids of interest into recipient cells are known and include lipofection, transfection, microinjection, transformation, microprojectic techniques, etc. Any suitable vector can be used, including plasmids, viruses (including retroviruses), phage, and the like, whether in native form or derivatives thereof.

20 The donor PGCs can be genetically modified so as to produce a desired result in the recipient bird (e.g., to express a transgene that effects sex determination). Alternatively, it can be intended that the genetic modification be passed on to the offspring of the chimeric bird and produce a desired effect therein.

25 Introduction of one or more heterologous nucleotide sequence(s) (e.g., a foreign or exogenous sequence or an extra or modified copy of an endogenous sequence) can be used in a variety of applications, for example, to produce a polypeptide of interest in the bird (e.g., in the plasma or eggs of such birds for convenient collection and purification). According 30 to this embodiment, the bird can be used essentially as a bioreactor. Polypeptides of interest include therapeutic (e.g., for veterinary or medical

uses) or immunogenic (e.g., for vaccines) polypeptides, antibodies (including, but not limited to antibody fragments and single chain antibodies), enzymes (e.g., industrial enzymes), hormones and growth factors, or any other protein of interest.

5 Alternatively, the polypeptide can be a reporter polypeptide that serves as a marker of the donor cells (e.g., Green Fluorescent Protein, β -galactosidase, alkaline phosphatase, β -lactamase, neomycin phosphotransferase, and chloramphenicol acetyltransferase). Markers can be used to monitor embryonic development and/or analyze cell fate and
10 migration, among other purposes (see e.g. Mozdziak *et al. Dev Dynamics* 226:439-445, 2003). This reference documents the first successful transgenic line of birds for cell fate analysis.

In other embodiments, the polypeptide is a therapeutic or immunogenic polypeptide or any other polypeptide that has a desired or
15 beneficial effect on the recipient bird, e.g., a polypeptide that has a desired phenotypic effect or enhances growth performance (including, but not limited to increased muscling and/or reduced fat deposition and/or improved feed to gain ratio), egg production, disease tolerance, and the like.

As a further alternative, the heterologous nucleic acid of interest can
20 encode an antisense nucleic acid, a ribozyme (e.g., as described in U.S. Patent No. 5,877,022) or any other non-translated RNA.

It will be understood by those skilled in the art that the heterologous nucleotide sequence(s) of interest can be operably linked to appropriate control sequences. For example, the heterologous nucleic acid can be
25 operably linked to expression control elements including, but not limited to transcription/translation control signals, origins of replication, polyadenylation signals, and internal ribosome entry sites (IRES), promoters, enhancers, and the like.

It will further be appreciated that a variety of promoter/enhancer elements can be used depending on the level and tissue-specific expression desired. The promoter/enhancer can be constitutive or inducible, depending

on the pattern of expression desired. The promoter/enhancer can be native or foreign and can be a natural or a synthetic sequence. By foreign or exogenous, it is intended that the transcriptional initiation region is not found in the wild-type host into which the transcriptional initiation region is 5 introduced. In particular embodiments, the heterologous nucleotide sequence(s) is operatively linked to the ovalbumin promoter or the lysozyme promoter.

In one embodiment, promoter/enhancer elements that are native to the target cell or subject to be treated are employed. In another 10 embodiment, promoters/enhancer elements that are native to the heterologous nucleic acid sequence are employed. The promoter/enhancer element is chosen so that it will function in the target cell(s) of interest. In still another embodiment, avian promoter/enhancer elements are employed. The promoter/enhance element can be constitutive or inducible.

15 Inducible expression control elements can be employed in those applications in which it is desirable to provide regulation of the over expression of the heterologous nucleic acid sequence(s). Inducible promoters/enhancer elements for gene delivery can be cell- or tissue-specific promoter/enhancer elements. Other inducible promoter/enhancer 20 elements include hormone-inducible and metal-inducible elements. Exemplary inducible promoters/enhancer elements include, but are not limited to, a Tet on/off element, a RU486-inducible promoter, an ecdysone-inducible promoter, a rapamycin-inducible promoter, and a metallothionein promoter.

25 In embodiments wherein which the heterologous nucleic acid sequence(s) will be transcribed and then translated in the target cells, specific initiation signals are generally required for efficient translation of inserted protein coding sequences. These exogenous translational control sequences, which can include the ATG initiation codon and adjacent 30 sequences, can be of a variety of origins, both natural and synthetic.

V. Methods of Increasing the Proportion of Male Birds in a Plurality of Bird Eggs

In birds, unlike mammals, it is the male that is the homogametic sex (ZZ) and the female which is the heterogametic sex (Zw). Therefore in birds, 5 it is the female that determines the gender of the offspring since she produces ova that carry the sex determinative chromosome: *i.e.* either the Z or the w chromosome. Thus, as noted herein, by transferring male primordial germ cells to female embryonic hosts, the percentage of Z-bearing ova produced by that host is increased and the percentage of male 10 offspring is increased. An increase in the percentage of male offspring from broiler flocks is economically desirable for the corresponding greater feed conversion ratio and more efficient meat production so obtained.

When the ZZ PGCs are administered to a male embryo, no sex ratio alteration should occur in the recipient's offspring regardless of the extent to 15 which the donor PGCs colonize the recipient's gonad. It is only when ZZ PGCs are administered to female (Zw) recipient embryos that sex ratio skewing can occur. Thus, the instant method can produce sex ratio skewing when ZZ PGCs are administered to female (Zw) embryos.

The degree to which Z-bearing ova are produced in the recipient 20 female embryo once it reaches sexual maturity, and thus the degree to which the recipient produces male offspring, can depend on the extent to which the donor ZZ PGCs colonize the gonad of the recipient embryo. Several possible outcomes can occur. At one end of the spectrum, the donor PGCs do not colonize the embryonic gonad, and thus the recipient 25 would be expected to produce 50% Z ova and 50% w ova (*i.e.* no sex ratio skewing will occur). At the other end of the spectrum, the donor PGCs completely colonize the embryonic gonad to the exclusion of endogenous PGCs, the recipient would be expected to produce only Z ova, and thus all progeny of the recipient would be male. Accordingly, the expected 30 percentage of male progeny that would be produced by a recipient female can be calculated as 50% + (the percent colonization of the embryonic

gonad by ZZ PGCs divided by 2), assuming that the donor PGCs and the endogenous PGCs are individually equally capable of producing ova (i.e. the ova produced reflect the percentage of endogenous and donor PGCs present in the embryonic gonad).

5 Given this expectation, maximizing the percent colonization of the embryonic gonad by ZZ PGCs should maximize the percentage of male offspring of the recipient female. Several methods can be used to accomplish this goal. One such method is to administer a sufficient number of donor PGCs to the recipient such that the donor PGCs significantly
10 outnumber endogenous PGCs. This approach would be expected to be most effective when the recipient embryo is at a stage prior to the stage at which PGCs migrate to the embryonic gonad.

Another method is to remove endogenous PGCs or inhibit their ability to colonize the embryonic gonad prior to the administration of donor PGCs.
15 This can be accomplished by physically removing the endogenous PGCs from the embryo, for example, by removing the blood from the embryo at a stage when the endogenous PGCs are circulating in the embryonic blood. See Naito *et al.*, *Mol Reprod Develop* 39:153, 1994; Tajima *et al.*, *J Exp Zool* 280:265, 1998. However, this is a technically demanding manipulation that
20 risks substantial damage to the embryo itself. An alternative is to prevent endogenous PGCs from reaching and/or colonizing the embryonic gonad. Several reports describe the use of chemicals or radiation to accomplish this goal, including busulfan (see Aige-Gil & Simkiss, *Res Vet Sci* 50:139, 1991; Vick *et al.*, *J Reprod Fert* 98:637; Bresler *et al.*, *Br Poutry Sci* 35:241, 1994;
25 Hallett & Wentworth, *Poultr Sci* 70:1619, 1991), Concanavalin-A (Lee *et al.*, *J Embryol Exp Morph* 46:5, 1978), and uv- or gamma-irradiation (Reynaud, *J Embryol Exp Morphol* 21:485-507, 1969; Reynaud, *J Roux's Arch Devel Biol* 179:85-110, 1976; Aige-Gil & Simkiss, *Br Poul Sci* 32:427-438, 1991; Reynaud, *C R Hebd Seances Acad Sci-D: Sci Natur* 282:1195, 1976; Mraz &
30 Woody, *Radiation Res* 54:63-68, 1973; Carsience *et al.*, *Development* 117:669-75, 1993; Thoraval *et al.*, *Poultry Sci* 73:1897-1905, 1994; Maeda

et al., *Poultry Sci* 77:905-07, 1998). The use of toxic chemical and radiation is not optimal, however, especially for agriculturally important avian species.

An alternative approach is disclosed herein, in which antibodies that recognize antigens associated with PGCs are deposited into the yolk of the
5 egg in which the recipient embryo develops as a result of immunization of the hen that produced the egg with the antigen. In this embodiment, female avians are immunized with an antigen associated with PGCs. Antibodies directed against the antigen are deposited into the yolk of eggs produced by the immunized females. The antibodies are then available to modulate the
10 development of PGCs in an embryo growing within the egg. In one embodiment, the antibodies produce a reduction in the number of PGCs present in the embryonic gonad, such that when donor PGCs are administered into the recipient embryo, the donor PGCs are able to colonize the gonad and develop therein. The recipient embryo is then incubated to
15 hatch, and allowed to reach sexual maturity.

When used for increasing the number or ratio of male birds hatched from a group of eggs, the presently disclosed subject matter involves administering to a female bird *in ovo* male (*i.e.* ZZ) avian primordial germ cells. The gender of the bird *in ovo* can be predetermined or determined
20 after hatch. The bird is then incubated to hatch, the gender of the bird determined if necessary, raised to sexual maturity, and bred by crossing the bird with a suitable male breeder stock in accordance with known techniques. A plurality of fertile eggs laid by that bird are then collected, and typically incubated to hatch and the resulting birds grown for at least two to
25 three weeks. The ratio of male to female bird eggs (or birds) produced from the female bird is greater than that obtained in the absence of administering the male primordial germ cells to that bird *in ovo*. Such methods are typically used on species of bird that are raised for meat production, such as chickens, turkeys, ducks, etc.

30 VI. Methods for Producing Avian Gametes

The presently disclosed subject matter also provides a method for

producing avian gametes. In one embodiment, the method is employed to produce avian gametes from a second avian species in a first avian species. In one embodiment, the method comprises (a) immunizing a female of the first avian species with an antigen associated with primordial germ cells, 5 whereby an egg produced by the female comprises a sufficiently high concentration of antibodies specific for the antigen to modulate PGC development of a recipient bird of the first avian species present within the egg; (b) introducing donor PGCs isolated from an avian of the second avian species into the recipient bird of the first avian species; (c) incubating the 10 recipient bird of the first avian species to hatch; and (d) raising the recipient bird of the first avian species to sexual maturity, wherein the recipient bird of the first avian species produces gametes from the second avian species.

When used for the production and collection of avian gametes (sperm, ova), the primordial germ cells that are administered *in ovo* to a 15 recipient species can be different from the donor species from which the donor PGCs were obtained. The recipient is then incubated to hatch and raised to sexual maturity, and sperm cells or ova of the donor species collected from the recipient animal, all in accordance with standard techniques. For example, in the case of an endangered species, the donor 20 avian species can be a whooping crane, and the recipient avian species can be a sand hill crane. In another example concerning commercial poultry production, the donor avian species can be a turkey, and the recipient avian species can be a chicken.

U.S. Patent Application Publication No. 20030111016 describes 25 approaches by the instant co-inventors to repopulate the embryonic gonad of one avian species with donor PGCs from another avian species. Barred Plymouth Rock (BPR) chicken embryos were incubated until stage 27-28 (H&H). Barred Plymouth Rock donor embryos were utilized as a color marker because they are homozygous recessive (ii) at the I locus and 30 express pigment in their plumage. The gonads from male embryos were collected in DMEM, supplemented with 10% FBS, glutamine, antibiotic and

antimycotic solution. Sex determination of the embryos was accomplished by utilizing the method of Petite & Kegelmeyer (*Animal Biotechnol* 6:19-30, 1995). The gonads were then rinsed twice in PBS and incubated in 0.02% EDTA at 37C for 15 minutes. Fresh media was added and the gonads were
5 teased apart.

The cell suspension was collected and spun at 450g for 5 minutes. The media was replaced and cell viability determined using trypan blue exclusion. Aliquots of the cell suspension were taken and stained with SSEA-1 antibody to determine the number of PGCs injected. Approximately
10 2-3 µl of cell suspension, containing 100-500 PGCs, was injected into the blood vessels of White Leghorn (WL) embryos at stages 14-17 (H&H) of development. The WL embryos served as recipients because they were known to be homozygous dominant (II). This genotype codes for an absence of pigment in the plumage. Following the PGC injection, the eggs
15 were returned to the incubator to complete development. At hatching the phenotypic WL chicks were banded and subsequently grown to sexual maturity. The following test matings were conducted to determine if germline chimeras existed: male BPR X female WL and male WL X female BPR. The offspring from these test matings were subsequently evaluated to determine
20 if male BPR gonadal PGC were incorporated in the WL. Since only male BPR embryos were used as donors, all "black" chicks (BPR-phenotype) derived from the male BPR X female WL test matings would be male.

Fertilized turkey eggs were incubated at 38.5°C for 8-8.5 days (stage 27-28, H&H). Embryos were dissected to obtain gonads. Then 2-3 µl of the
25 gonadal cell suspension, containing approximately 150 PGCs, was injected into the blood vessels stage 14 (H&H) chick embryos. The recipient eggs were sealed and returned to the incubator. Recipient embryos were collected at different stages of incubation (stage 19 to stage 25). The embryos were rinsed in PBS thrice and then fixed in 4% paraformaldehyde
30 overnight at 4°C. Samples were washed three times in PBS and then placed in 50% ethanol. The tissues were then dehydrated, embedded in

paraffin, and sectioned. The resulting sections were subsequently analyzed immunohistochemically by staining for SSEA-1 and periodic acid-Schiff (PAS). Previous research has identified a species difference in the expression of SSEA-1 by turkey and chick PGCs. This antigenic variation
5 coupled with the standard PAS test can be used for identifying turkey-chick germline chimeras. Observations of the double stained chick embryonic sections verified that chick PGCs are both PAS positive and SSEA-1 positive. Double staining of the stage 24 turkey sections with PAS and SSEA-1 verified that turkey PGCs migrating through the dorsal mesentery
10 and colonizing the gonad are PAS positive and do not express the SSEA-1 epitope. Hence, double staining of chick and turkey embryos verified that the double staining technique could be used as a marker for distinguishing PGCs from turkey versus PGCs from chicken.

Offspring from a WL (II) X BPR (ii) cross would typically express the
15 WL phenotype (ii) and exhibit an absence of melanin pigment in the plumage. The introduction of male BPR PGC into WL recipients resulted in offspring that demonstrated the black pigment pattern of the BPR. These data support the concept that there are no biological barriers that would prevent the production of increased male offspring by injecting female chick
20 embryos with PGC isolated from the gonads of male embryos. However, the incidence of germline transmission was less than 1%. The low incidence of donor-derived offspring in this system was possibly related to the significant numerical advantage that endogenous PGCs exhibited when compared to the number of injected donor PGCs. The treatment of embryos with a BU +
25 DMF + SO emulsion prior to the injection of donor PGC reduced the number of endogenous PGC by as much as 97%. When compared to BU + SO alone, the addition of DMF increased the reduction in endogenous PGC by approximately 15%.

Following the double staining with SSEA-1 and PAS; chick and turkey
30 PGC were identified in the chick embryonic gonad on the basis of differing staining patterns. Due to the presence of glycogen, both chick and turkey

PGCs stain a magenta color following PAS staining. However, turkey PGCs are no longer SSEA-1 positive when they take residence in the developing gonad, distinguishing them from PGCs of the chick which are SSEA-1 positive at this stage of development. These results suggest that PGCs
5 isolated from the embryonic turkey gonad can be used to repopulate the chick gonad.

Continuing with reference to U.S. Patent Application Publication No. 20030111016, white leghorn (WL) embryos were treated *in ovo* with a busulfan emulsion (BU + DMF + sesame oil) to deplete endogenous PGCs.
10 Gonads from male Barred Plymouth Rock (BPR) embryos were collected, PGCs isolated, and the isolated PGCs administered to the busulfan emulsion treated birds and control untreated birds *in ovo*, essentially as described in the preceding example. After hatch, male WL chimeric birds were raised to sexual maturity and crossed with female BPR birds.
15 Production of black offspring is indicative of transmission of the gametes derived from the BPR PGCs by the chimeric male WL parent. Results indicated that 25% (4/16) WL males are transmitting gametes derived from the BPR PGCs. Among these 4 chimeric birds, the rate of transmission is between about 2% to 23%. In the control birds that were not subjected to
20 busulfan treatment, only one bird had any detectable transmission of the gametes derived from the BPR PGCs.

In some embodiments, the presently disclosed subject matter implements methods to repopulate the embryonic gonad of one avian species with donor PGCs from another avian species as disclosed in U.S. Patent Application Publication No. 20030111016. Of course, in such embodiments, the presently disclosed subject matter also implements the immunizing a female of the first avian species with an antigen associated with primordial germ cells, whereby an egg produced by the female comprises a sufficiently high concentration of antibodies specific for the
25 antigen to modulate PGC development of a recipient bird of the first avian species present within the egg.
30

VII. Methods for Enhancing Germ Line Transmission of a Nucleic Acid Molecule

The presently disclosed subject matter also provides a method for enhancing germ line transmission of a nucleic acid molecule in a bird. In 5 one embodiment, the method comprises (a) immunizing a female bird with an antigen associated with primordial germ cells, whereby an egg produced by the female bird comprises a sufficiently high concentration of antibodies specific for the antigen to modulate PGC development in a recipient bird present within the egg; (b) administering a plurality of donor PGCs 10 comprising the nucleic acid molecule to the recipient bird under conditions sufficient to allow at least one of the plurality of PGCs to colonize a gonad of the recipient bird; (c) incubating the recipient bird to hatch; and (d) raising the recipient bird to sexual maturity, wherein the recipient bird produces gametes derived from the donor PGCs. In this embodiment, germ line 15 transmission is rendered more efficient than current state of the art methods, in which the efficient generation of germ line chimeras continues to be a need in the art.

The instant method is based upon the same principles discussed hereinabove that relate to the production of germ line chimeras generally. In 20 this embodiment, however, the donor PGCs are manipulated *in vitro* prior to administration into the recipient embryo by introducing into the PGCs an exogenous nucleic acid molecule (*i.e.* a transgene). The method is not limited either by the nucleic acid itself (for example, an open reading frame of interest operably linked to a promoter) or to the method of introduction (for 25 example, electroporation, liposome-mediated transfection, etc.). Rather, a nucleic acid of interest is introduced into a plurality of donor PGCs using techniques known in the art, which are then administered to a recipient embryo developing in an egg produced by a female avian that had been immunized with an antigen associated with PGCs. The donor PGCs are 30 then allowed to colonize the gonad of the embryo, which when it reaches sexual maturity, can transmit the nucleic acid to its offspring.

VIII. Administration

Primordial germ cells (PGCs) can be provided and formulated for carrying out the presently disclosed subject matter by any suitable technique, and stored, frozen, cultured, or the like prior to use as desired.

5 For example, primordial germ cells can be collected from donor embryos at an appropriate embryonic stage. Stages of avian development are referred to herein by one of two art-recognized staging systems: the Eyal-Giladi & Kochav system (EG&K; see Eyal-Giladi & Kochav, *Dev Biol* 49:321-327, 1976), which uses Roman numerals to refer to pre-primitive streak stages of

10 development, and the Hamburger & Hamilton staging system (H&H; see e.g., Hamburger & Hamilton, *J Morphol* 88:49-92, 1951), which uses Arabic numerals to reference to post-laying stages. Unless otherwise indicated, the stages referred to herein are stages as per the H&H staging system.

For example, PGCs can be isolated at stage 4, or the germinal crescent stage, through stage 30, with cells being collected from blood, genital ridge, or gonad in the later stages. The primordial germ cells are, in general, twice the size of somatic cells and easily distinguished and separated therefrom on the basis of size. Male (or homogametic) primordial germ cells (ZZ) can be distinguished from heterogametic primordial germ cells (Zw) by any suitable technique, such as collecting germ cells from a particular donor and typing other cells from that donor, the collected cells being of the same chromosome type as the typed cells.

PGCs can be formulated for administration to animals by dissociating the cells (e.g., by mechanical dissociation) and intimately admixing the cells with a pharmaceutically acceptable carrier (e.g., phosphate buffered saline solution). The primordial germ cells are in one embodiment gonadal primordial germ cells, and in another embodiment blood primordial germ cells ("gonad" or "blood" referring to their tissue of origin in the original embryonic donor). The primordial germ cells administered can be heterogametic (Zw) or homogametic (ZZ) depending upon the particular object of the administration. PGCs can be administered in physiologically

acceptable carrier, in one embodiment at a pH of from about 6 to about 8 or 8.5, in a suitable amount to achieve the desired effect (e.g., 100 to 1000 PGCs per embryo). The PGCs can be administered free of other ingredients or cells, or other cells and ingredients can be administered along with the
5 PGCs.

Administration of the primordial germ cells to the recipient animal *in ovo* can be carried out at any suitable time at which the PGCs can still migrate to the developing gonads. In one embodiment, administration is carried out from about stage IX according to the Eyal-Giladi & Kochav
10 (EG&K) staging system to about stage 30 according to the Hamburger & Hamilton staging system of embryonic development, and in another embodiment, at stage 15. For chickens, the time of administration is thus during days 1, 2, 3, or 4 of embryonic development: in one embodiment day 2 to day 2.5. Administration is typically by injection into any suitable target
15 site, such as the region defined by the amnion (including the embryo), the yolk sac, etc. In one embodiment, injection is into the embryo itself (including the embryo body wall), and in alternative embodiments, intravascular or intracoelomic injection into the embryo can be employed. The methods of the presently disclosed subject matter can be carried out
20 with prior sterilization of the recipient bird *in ovo* (by "sterilization" is meant to render partially or completely incapable of producing gametes derived from endogenous PGCs). When donor gametes are collected from such a recipient, they can be collected as a mixture with gametes of the donor and the recipient. This mixture can be used directly, or the mixture can be further
25 processed to enrich the proportion of donor gametes therein.

Administration of PGCs can be carried out by administering PGCs per se, or by administering precursor cells that develop into PGCs in the subject (particularly where the methods disclosed herein are employed to alter the sex ratio of offspring). For example, administration can be carried out by
30 injecting the bird with blastodermal cells, where a subset of the blastodermal cells differentiates into primordial germ cells *in vivo* in the bird.

The *in ovo* administration of the primordial germ cells can be carried out by any suitable technique, either manually or in an automated manner. In one embodiment, *in ovo* administration is performed by injection. The mechanism of *in ovo* administration is not critical, but it is the mechanism
5 should not unduly damage the tissues and organs of the embryo or the extraembryonic membranes surrounding it so that the treatment will not unduly decrease hatch rate. A hypodermic syringe fitted with a needle of about 18 to 26 gauge is suitable for the purpose. Depending on the precise stage of development and position of the embryo, a one-inch needle will
10 terminate either in the fluid above the chick or in the chick itself. A pilot hole can be punched or drilled through the shell prior to insertion of the needle to prevent damaging or dulling of the needle. If desired, the egg can be sealed with a substantially bacteria-impermeable sealing material such as wax or the like to prevent subsequent entry of undesirable bacteria. It is envisioned
15 that a high-speed injection system for avian embryos will be particularly suitable for practicing the presently disclosed subject matter. Numerous such devices are available, an exemplary device being the EMBREX INOVOJECT™ system (described in U.S. Patent Nos. 4,681,063 and 4,903,625 to Hebrank), as well as devices described in U.S. Patent Nos.
20 4,040,388; 4,469,047; and 4,593,646 to Miller. The disclosure of all United States patent references cited herein are be incorporated herein by reference in their entirety. All such devices, as adapted for practicing the methods disclosed herein, comprise an injector containing the a formulation of the primordial germ cells as described herein, with the injector positioned
25 to inject an egg carried by the apparatus in the appropriate location within the egg as discussed above. In addition, a sealing apparatus operatively connected to the injection apparatus can be provided for sealing the hole in the egg after injection thereof.

Examples

30 The presently disclosed subject matter will be now be described more fully hereinafter with reference to the accompanying Examples, in which

representative embodiments of the presently disclosed subject matter are shown. The presently disclosed subject matter can, however, be embodied in different forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the presently disclosed subject matter to those skilled in the art.

Example 1

Immunization of Female Birds

Antigenic peptide regions of chicken DAZL and chicken VASA homolog proteins were identified, synthesized, and conjugated to keyhole limpet hemocyanin (KLH). Selected peptides are shown in Table 1.

Table 1

Selected Peptides for Conjugation and Immunization of Laying Hens Against Chicken VASA and DAZL

Designation	Amino Acid Sequences	Location of Peptide
VASA-N	SRP SSP LSG FPG RPN S (SEQ ID NO: 3)	amino acids 42-57 of the chicken VASA homologue (CVH; GENBANK® Accession No. BAB12337)
VASA-C	NPR EMR MSY SET TFK S (SEQ ID NO: 4)	amino acids 645-660 of the chicken VASA homologue (CVH; GENBANK® Accession No. BAB12337)
DAZL-N	SAN AEA QCG SIS EDN TH (SEQ ID NO: 7)	amino acids 2-17 of the chicken DAZL polypeptide (GENBANK® Accession No. AAO26019)
DAZL-C	SQE DYF RER AHH FRK G (SEQ ID NO: 8)	amino acids 266-281 of the chicken DAZL polypeptide (GENBANK® Accession No. AAO26019)

Stock solutions (1,000 µg/ml) of the various conjugated peptides were maintained at 4°C. Immediately prior to immunization, a stable emulsion was produced from 0.5 ml of conjugated peptide and 0.5 ml of TITERMAX® adjuvant (TMA; CytRx Corp., Norcross, Georgia, United States of America) utilizing two syringes connected by a double hub emulsifying needle. TMA is a synthetic nonionic block copolymer of polyoxyethylene and polyoxypropylene.

Sexually mature Leghorn females were immunized intramuscularly with 100-200 µg of a single conjugated peptide or combination of peptides (pectoralis major). Blood samples were taken after immunization, allowed to clot over night at 4°C, and the resulting serum samples were stored at -20°C for subsequent antibody determination. A secondary immunization (50-100 µg of conjugated peptide + TMA) was administered 14 days later. Blood samples were also obtained three days following the second challenge from both immunized hens and non-injected controls. The resulting serum samples were stored at -20°C for subsequent antibody determination.

Titers of anti-peptide antibodies were determined using an indirect ELISA technique. Antigen (*i.e.* KLH-conjugated peptide) solutions were prepared by dissolving the antigen in distilled water at a concentration of 20 µg/ml (1 mg in 50 ml). If the antigen was not immediately soluble, the pH was adjusted with 1N NaOH or 1N HCl until the antigen dissolved. To prepare ELISA plates, antigen solution (0.1 ml) was added to each well of a 96-well high-binding microtiter plate. The plate was then covered with an adhesive film and incubated overnight at room temperature or two hours at 37°C. Following the incubation period, the plates were washed three times with 200 µl of 0.05% Tween-20/PBS (pH 7.4, vol:vol). Plates were then blotted on paper towel to remove the excess Tween-20/PBS. Blocking solution (1% BSA in PBS, pH 7.4, stored at 4°C) was then added (150 µl) to each well. Plates were covered with adhesive film and incubate at least 2 hr at room temperature or 1 hour at 37°C or indefinitely at 4-8°C.

The plates were then washed an additional three times with 200 µl of

0.05% Tween-20/PBS (pH 7.4, vol:vol) and blotted on paper towel to remove the excess washing solution. Test or naive animal serum in 1% BSA/PBS buffer was serially diluted (1:100 - 1:1,000,000). Duplicate samples of 100 µl of the test or control (*i.e.* non-immunized) chicken serum dilutions were 5 added. The plates were covered and incubated overnight at 4-8°C or 2 hour at 37°C.

Plates were washed three times with 200 µl of 0.05% Tween-20/PBS (pH 7.4, vol:vol) and blotted on paper towel to remove the excess washing solution. 100 µl of goat or donkey anti-chicken (IgM + IgG) HRP conjugate 10 solution (diluted 1:6000) in 1% BSA/PBS buffer was added to each well. The plates were covered with adhesive film and incubated at least 4 hour at room temperature or 2 hour at 37°C or overnight at 4-8°C. Following incubation, the plates were once again washed three times with 200 µl of 0.05% Tween-20/PBS (pH 7.4, vol:vol) and blotted on paper towel to remove 15 the excess washing solution.

Finally, 100 µl of substrate solution was added to each well. The substrate solution was prepared by adding 200 µl of a 2,2'-azino-bis-(3-benzthiazoline-6-sulfonic acid (ABTS) dye solution (prepared by dissolving 15 mg ABTS dye in 1 ml de-ionized water) and 10 µl H₂O₂ to 10 ml 0.05 M 20 citrate buffer, pH 4.0. After addition of the substrate, the plates were allowed to incubate at room temperature and then analyzed on a plate reader at 405 nm. Titers were assigned as the last dilution that resulted in a signal that was statistically significantly higher than background (*i.e.* serum isolated from a non-immunized control hen) at 405 nm. Titers of antibodies from 25 representative hens are shown in Table 2.

Table 2

Serum Titers Against Chicken VASA and DAZL Peptide Conjugates After Immunization of Laying Hens

Bird #	Antigen	Titer 17 days	Titer 40 days
		after immunization	after immunization
522	Vasa-C	1:10,000	1:10,000

524	Vasa-C	1:1,000	1:5,000
538	Dazl-C	1:1,000	1:5,000
548	Vasa-C	1:1,000	1:5,000
	Vasa-N	1:1,000	1:10,000
550	Vasa-C	1:1,000	1:5,000
	Vasa-N	1:1,000	1:5,000
552	Vasa-C	1:500	1:1,000
	Vasa-N	1:1,000	1:1,000
554	Dazl-C	1:10,000	1:50,00
	Dazl-N	1:10,000	1:50,00
556	Dazl-C	1: 100,000	1: 100,000
	Dazl-N	1:1,000,000	1:1,000,000
566	Vasa-C	no reaction	1:10,000
	Vasa-N	1:10,000	1:50,000
	Dazl-C	no reaction	1:5,000
	Dazl-N	1:5,000	1:10,000

Example 2

Evaluation of PGCs in Stage 27 Embryos

After immunization, eggs were collected, stored for a maximum of 14 days, and incubated to reach stage 27 (H&H). Stage 27 (H&H) embryos 5 were sacrificed and fixed in 4% paraformaldehyde overnight at 4°C. The embryos were then embedded in paraffin and serially sectioned across the gonadal region at 7 µm thickness. The slides containing gonadal region were selected from other slides and the PGCs in gonads were identified by immunohistological staining using monoclonal antibody MC-480 10 (Developmental Studies Hybridoma Bank, The University of Iowa, Iowa City, Iowa, United States of America) that recognizes the stage-specific embryonic antigen-1 (SSEA-1). The immunohistological staining was carried out using avidin-biotin conjugated alkaline phosphatase (VECTASTAIN® ABC-AP kit, Vector Laboratories, Burlingame, California, United States of 15 America) and BCIP/NBT (5-bromo-4-chloro-3-indolyl phosphate/nitroblue

tetrazolium) substrate (Amresco, Inc., Solon, Ohio, United States of America). Briefly, after blocking in 1.5% normal goat serum in PBS for 30 minutes to eliminate nonspecific staining, sections were sequentially incubated at room temperature with the primary antibody (1:1000 diluted 5 ascites) for 60 minutes and rinsed 3 times with PBS, biotinylated second antibody for 30 minutes rinsed 3 times with PBS, and ABC reagent for 30 minutes. After a final wash in PBS, sections were stained in the alkaline phosphatase substrate (NBT/BCIP solution, Amresco) for 15 minutes, and then mounted in an aqueous mounting medium. Representative sections 10 are shown in Figures 1-3.

In Figure 1, the hen that produced the egg in which the depicted embryo developed was immunized with peptides derived from the chicken VASA polypeptide. Panel A: control (no immunization); Panel B: immunization with Vasa-C peptide (SEQ ID NO: 4); Panel C: immunization 15 with Vasa-N peptide (SEQ ID NO: 3); Panel D: immunization with both Vasa-N and Vasa-C. SSEA-1⁺ cells (dark stained cells) are much more abundant in the control embryo than in any of the embryos exposed to anti-VASA antibodies.

In Figure 2, the hen that produced the egg in which the depicted 20 embryo developed was immunized with peptides derived from the chicken DAZL polypeptide. Panel A: control (no immunization); Panel B: immunization with DAZL-C peptide (SEQ ID NO: 8); Panel C: immunization with DAZL-N peptide (SEQ ID NO: 7); Panel D: immunization with both DAZL-N and DAZL-C. SSEA-1⁺ cells (dark stained cells) are much more 25 abundant in the control embryo than in any of the embryos exposed to anti-DAZL antibodies.

In Figure 3, the hen that produced the egg in which the depicted embryo developed was immunized with peptides derived from both the chicken VASA and DAZL polypeptides. Panel A: control (no immunization); 30 Panel B: immunization with Vasa-N, Vasa-C, DAZL-N, and DAZL-C peptides (SEQ ID NOS: 3, 4, 7, and 8). SSEA-1⁺ cells (dark stained cells) are much

more abundant in the control embryo than in the embryo exposed to both anti-VASA and anti-DAZL antibodies.

Reduction of PGCs was determined by counting immunohistochemically stained PGCs in 10 sections of both left and right 5 gonads of each embryo. The 10 sections were selected from the mid-region of the gonads. At least three sections were skipped between any two selected sections to avoid counting individual PGCs more than once. The results of this analysis are presented in Figure 4. As shown in Figure 4, each of the peptide antigens Vasa-N, Vasa-C, Dazl-N, and Dazl-C were able 10 to induce an immune response in chickens, which resulted in the deposition of anti-antigen antibodies in the yolk of eggs produced by the immunized females. The presence of the antibodies in the eggs reduced PGCs numbers in developing stage 27 embryos. Immunizing females with individual peptides resulted in an approximately 35-55% reduction in 15 endogenous PGC numbers, while immunization with two or more peptides simultaneously resulted in an approximately 55-70% reduction in endogenous PGCs.

Statistical analysis. Treatment differences for the average number of PGCs/embryo were analyzed using the GLM procedure of the SAS System 20 (SAS Institute Inc., Cary, North Carolina, United States of America). The model was PGC = treatment hen. Treatment differences were significant at p < .0002. Means were separated using Duncan's Multiple Range Test. All treatments were significantly different from Control with the exception of Vasa-N.

25

Example 3

Repopulating Germ Cells in Treated Embryos

Birds produced in accordance with Examples 1 and 2 are used as recipients and administered exogenous PGCs from donor birds.

A. Preparation of Donor Cells:

30 Gonads from 5.5-day chicken embryos are collected in PBS. The isolated gonads are pooled in 250 µl of 0.02% EDTA in a 35 mm petri dish

and are incubated at 37°C for 10 minutes. The gonads are teased with a needle in the petri dish and are incubated at 37°C for 5 more minutes. The cells are collected in DMEM containing 20% FBS and centrifuged at 450 g for 5 minutes. The cells are washed and resuspended in DMEM. The cells 5 number and viability are determined. The final concentration of viable cells is adjusted to about 1000 cells/ μ l.

B. Preparation of Recipient Embryos:

Recipient chick embryos are prepared as described in Examples 1 and 2. The embryos are placed in the incubator until Stage 14-17 (H&H).

10 C. Injection of Donor PGCs into Recipient Embryos:

Approximately 2 to 3 μ l of gonadal cell suspension containing approximately 100 PGCs is injected into the blood vessel of stage 14-17 (H&H) recipient chick embryos. The recipient eggs are sealed and incubated at 37.5°C, 60% relative humidity.

15 D. Assessment of PGC Repopulation:

The embryos are collected at stage 27 (H&H) and fixed in 4% paraformaldehyde overnight at 4°C. The embryos are embedded in paraffin, sectioned at 7 μ m thickness and stained immunohistochemically with SSEA-1 antibody. The number of PGCs in the left and right gonad in 10 randomly 20 selected sections from control and PGC injected embryos is counted. The results are analyzed statistically by applying a t-test performed to test the null hypothesis that the difference between the means of the populations from which the two samples come equals 0.0 versus the alternative hypothesis that the difference is not equal to 0.0. If the p-value for this test is 25 less than 0.05, the null hypothesis can be rejected at the 95.0% confidence level. Also determined is a 95.0% confidence interval for the difference between the population means. In repeated sampling, 95.0% of all such intervals will contain the true difference.

Example 4Production of Intra-Specific Chicken Germline Chimeras after
Depletion of Endogenous PGCs

The following procedure is used to produce intra-specific germline
5 chimeras:

A. Production of Intra-Specific Chicken Germline Chimeras

Barred Plymouth Rock (BPR) chicken embryos are incubated until stage 27-28 (H&H). Barred Plymouth Rock donor embryos are utilized as a color marker because they are homozygous recessive (ii) at the I locus and 10 express pigment in their plumage. The gonads from male embryos are collected in DMEM, supplemented with 10% FBS, glutamine, antibiotic and antimycotic solution. Sex determination of the embryos is accomplished by utilizing the method of Petitte & Kegelmeyer (*Animal Biotechnol* 6:19-30, 1995). The gonads are then rinsed twice in PBS and incubated in 0.02% 15 EDTA at 37°C for 15 minutes. Fresh media is added and the gonads are teased apart.

The cell suspension is collected and spun at 450 x g for 5 minutes. The media is replaced and cell viability determined using trypan blue exclusion. Aliquots of the cell suspension are taken and stained with SSEA-20 1 antibody to determine the number of PGCs injected. Approximately 2-3 µl of cell suspension, containing 100-500 PGCs, was injected into the blood vessels of White Leghorn (WL) embryos at stages 14-17 (H&H) of development. The WL embryos served as recipients because they were known to be homozygous dominant (II). This genotype codes for an 25 absence of pigment in the plumage. Following the PGC injection, the eggs were returned to the incubator to complete development. At hatching the phenotypic WL chicks were banded and subsequently grown to sexual maturity. The following test matings were conducted to determine if germline chimeras existed: male BPR X female WL (BPR PGC) and male WL (BPR 30 PGC) X female BPR. The offspring from these test matings were subsequently evaluated to determine if male BPR gonadal PGC were

incorporated in the WL. Since only male BPR embryos were used as donors, all "black" chicks (BPR-phenotype) derived from the male BPR X female WL (BPR PGC) test matings would be male.

B. Preparation of Recipient Embryos:

5 Recipient chick embryos are prepared as described in Examples 1 and 2. The embryos are collected at stage 27 (H&H) and fixed in 4% paraformaldehyde overnight at 4°C. The embryos are embedded in paraffin, sectioned at 7 µm thickness and are stained immunohistochemically with SSEA-1 antibody. The number of PGCs in the left and right gonad in 10 randomly selected sections from each embryo is counted. The index of 10 sterility (IS) is calculated using the equation IS = (N-X)/N where N is the PGC number from control gonads and X is the PGC number from treated embryo (Reynaud, *J Embryol Exp Morphol* 21:485-507, 1969).

C. Production of Inter-specific Turkey-Chicken Embryonic
15 Germline Chimeras

Fertilized turkey eggs are incubated at 38.5°C for 8-8.5 days (stage 27-28, H&H). Embryos are dissected to obtain gonads. Then 2-3 µl of the gonadal cell suspension, containing approximately 150 PGCs, is injected into the blood vessels stage 14 (H&H) chick embryos. The recipient eggs 20 are sealed and returned to the incubator. Recipient embryos are collected at different stages of incubation (stage 19 to stage 25). The embryos are rinsed in PBS thrice and then fixed in 4% paraformaldehyde overnight at 4°C. Samples are washed three times in PBS and then placed in 50% ethanol. The tissues are then dehydrated, embedded in paraffin, and 25 sectioned. The resulting sections are subsequently analyzed immunohistochemically by staining for SSEA-1 and periodic acid-Schiff (PAS).

D. Results

Following the double staining with SSEA-1 and PAS, chick and turkey 30 PGC are identified in the chick embryonic gonad on the basis of differing staining patterns. Due to the presence of glycogen, both chick and turkey

PGC stain a magenta color following PAS staining. However, turkey PGC are no longer SSEA-1 positive when they take residence in the developing gonad, distinguishing them from PGC of the chick which are SSEA-1 positive at this stage of development.

5 Offspring from a WL (II) X BPR (ii) cross would typically express the WL phenotype (ii) and exhibit an absence of melanin pigment in the plumage.

Example 5

Production of Intra-Specific Chimeras and Test Mating

10 Using similar protocols to those described in the previous Examples, white leghorn (WL) embryos are treated to deplete endogenous PGCs. Gonads from male Barred Plymouth Rock (BPR) embryos are collected, PGCs are isolated, and the isolated PGCs are administered to the treated birds and control untreated birds *in ovo*, essentially as described in the
15 preceding example. After hatch, male WL (BPR PGC) chimeric birds are raised to sexual maturity and crossed with female BPR birds. Production of black offspring is indicative of transmission of the gametes derived from the BPR PGCs by the chimeric male WL (BPR PGC) parent.

It will be understood that various details of the presently disclosed
20 subject matter can be changed without departing from the scope of the presently disclosed subject matter. Furthermore, the foregoing description is for the purpose of illustration only, and not for the purpose of limitation.

CLAIMS

What is claimed is:

1. A method for modulating primordial germ cells numbers in an avian embryo, the method comprising immunizing a female bird with an antigen associated with primordial germ cells, whereby an egg produced by the female bird comprises a sufficiently high concentration of antibodies specific for the antigen to modulate numbers of endogenous PGCs in an avian embryo present within in the egg.
2. The method according to Claim 1, wherein the female bird is selected from the group consisting of chicken, turkey, duck, quail, and sand hill crane.
3. The method according to claim 3, wherein the female bird is a chicken.
4. The method according to Claim 1, wherein the antigen comprises an epitope of a polypeptide selected from the group consisting of SSEA-1, VASA, EMA-1, germ cell-less, dead end, nanos, stella, fragilis, and DAZL.
5. The method of claim 1, wherein the immunizing step results in a decrease in primordial germ cell numbers in the avian embryo.
6. The method of claim 1, wherein the immunizing step results in an increase in primordial germ cell numbers in the avian embryo.
7. A method for modulating primordial germ cell development in an avian embryo, the method comprising immunizing a female bird with an antigen associated with primordial germ cells, whereby an egg produced by the female bird comprises a sufficiently high concentration of antibodies specific for the antigen to modulate development of PGCs in an avian embryo present within the egg.
8. The method according to Claim 7, wherein the antigen comprises an epitope of a polypeptide selected from the group consisting of SSEA-1, VASA, EMA-1, germ cell-less, dead end, nanos, stella, fragilis, and DAZL.
9. The method according to Claim 7, wherein the female bird is selected from the group consisting of chicken, turkey, duck, quail, and sand hill crane.

hill crane.

10. The method according to claim 9, wherein the female bird is a chicken.

11. The method of claim 7, wherein the immunizing step results in an
5 inhibition of development of the primordial germ cells in the avian embryo.

12. The method of claim 7, wherein the immunizing step results in an enhancement of development of the primordial germ cells in the avian embryo.

13. A method for producing a chimeric avian, the method comprising:
10 (a) immunizing a female avian with an antigen associated with primordial germ cells;
(b) producing an egg from the female bird, wherein the egg comprises a sufficiently high concentration of antibodies specific for the antigen to modulate PGC development, PGC numbers, or combinations thereof, in a recipient embryo present within the egg; and
15 (c) administering donor PGCs to the recipient embryo *in ovo* to produce a chimeric avian.

14. The method according to Claim 13, wherein the antigen
20 comprises an epitope of a polypeptide selected from the group consisting of SSEA-1, VASA, EMA-1, germ cell-less, dead end, nanos, stella, fragilis, and DAZL.

15. The method according to Claim 13, wherein the donor PGCs are from the same avian species as the recipient embryo.

25 16. The method according to Claim 13, wherein the donor PGCs are from a different avian species as the recipient embryo.

17. The method according to Claim 13, further comprising incubating the chimeric avian to hatch.

18. The method according to Claim 13, wherein the female avian is
30 selected from the group consisting of chicken, turkey, duck, quail, and sand hill crane.

19. The method according to Claim 13, wherein the donor PGCs are from an avian embryo selected from the group consisting of chicken, turkey, duck, quail, and whooping crane.

20. The method according to Claim 13, wherein the donor PGCs carry
5 a pair of male determinative (Z) chromosomes.

21. The method according to Claim 13, wherein the donor PGCs carry a female determinative (w) chromosome.

22. The method according to Claim 13, wherein the administering is by *in ovo* injection.

10 23. The method according to Claim 13, wherein the donor PGCs are administered when the recipient embryo is between about stage IX according to the Eyal-Giladi & Kochav staging system and about stage 30 according to the Hamburger & Hamilton staging system.

15 24. The method according to Claim 13, wherein the donor PGCs are administered when the recipient embryo is after stage 14 according to the Hamburger & Hamilton staging system.

25. The method according to Claim 13, wherein the donor PGCs are selected from the group consisting of gonadal PGCs, blood PGCs, and germinal crescent PGCs.

20 26. The method according to claim 13, wherein the administering step is carried out by injecting the recipient embryo with blastodermal cells, and wherein the blastodermal cells differentiate into donor PGCs in the recipient embryo.

25 27. A method for increasing the proportion of male birds in a plurality of bird eggs, the method comprising:

- (a) immunizing a female bird with an antigen associated with primordial germ cells;
- (b) producing an egg from the female bird, whereby the egg comprises a sufficiently high concentration of antibodies specific for the antigen to modulate PGC development in a recipient female bird present within the egg;

- (c) administering male (ZZ) PGCs to the recipient female bird *in ovo*;
 - (d) incubating the recipient female bird to hatch;
 - (e) raising the recipient female bird to sexual maturity; and
- 5 (f) producing from the recipient female bird a plurality of bird eggs, wherein the proportion of male birds in the plurality of bird eggs produced by the recipient female bird is higher than would have been obtained in the absence of administering the male (ZZ) PGCs to the recipient female bird *in ovo*.
- 10 28. The method according to Claim 27, wherein the antigen comprises an epitope of a polypeptide selected from the group consisting of SSEA-1, VASA, EMA-1, germ cell-less, dead end, nanos, stella, fragilis, and DAZL.
- 15 29. The method according to Claim 27, wherein the donor PGCs are from the same avian species as the recipient embryo.
30. The method according to Claim 27, wherein the donor PGCs are from a different avian species as the recipient embryo.
- 20 31. The method according to Claim 27, wherein the female avian is selected from the group consisting of chicken, turkey, duck, quail, and sandhill crane.
32. The method according to Claim 27, wherein the donor PGCs are from an avian embryo selected from the group consisting of chicken, turkey, duck, quail, and whooping crane.
- 25 33. The method according to Claim 27, wherein the administering is by *in ovo* injection.
34. The method according to Claim 27, wherein the donor PGCs are administered when the recipient embryo is between about stage IX according to the Eyal-Giladi & Kochav staging system and about stage 30 according to the Hamburger & Hamilton staging system.
- 30 35. The method according to Claim 27, wherein the donor PGCs are administered when the recipient embryo is after stage 14 according to the

Hamburger & Hamilton staging system.

36. The method according to Claim 27, wherein the PGCs are selected from the group consisting of gonadal PGCs, blood PGCs, and germinal crescent PGCs.

5 37. The method according to claim 27, wherein the administering step is carried out by injecting the recipient embryo with blastodermal cells, and wherein the blastodermal cells differentiate into donor PGCs in the recipient female bird.

10 38. A method for producing avian gametes from a second avian species in a first avian species, the method comprising:

- (a) immunizing a female of the first avian species with an antigen associated with primordial germ cells, whereby an egg produced by the female comprises a sufficiently high concentration of antibodies specific for the antigen to modulate PGC development of a recipient bird of the first avian species present within the egg;
- (b) introducing donor PGCs isolated from an avian of the second avian species into the recipient bird of the first avian species;
- (c) incubating the recipient bird of the first avian species to hatch; and
- (d) raising the recipient bird of the first avian species to sexual maturity, wherein the recipient bird of the first avian species produces gametes from the second avian species.

25 39. The method of Claim 38, wherein the antigen comprises an epitope of a polypeptide selected from the group consisting of SSEA-1, VASA, EMA-1, germ cell-less, dead end, nanos, stella, fragilis, and DAZL.

40. The method according to Claim 38, wherein the first avian species and the second avian species are each selected from the group consisting of chicken, turkey, duck, quail, sand hill crane, and whooping crane.

30 41. The method according to Claim 38, wherein the first avian species and the second avian species are the same.

42. The method according to Claim 38, wherein the first avian species and the second avian species are different.

43. The method according to Claim 38, wherein the administering is by *in ovo* injection.

5 44. The method according to Claim 38, wherein the donor PGCs are administered when the recipient bird of the first avian species is between about stage IX according to the Eyal-Giladi & Kochav staging system and about stage 30 according to the Hamburger & Hamilton staging system.

10 45. The method according to Claim 38, wherein the donor PGCs are administered when the recipient bird of the first avian species is after stage 14 according to the Hamburger & Hamilton staging system.

46. The method according to Claim 38, wherein the PGCs are selected from the group consisting of gonadal PGCs, blood PGCs, and germinal crescent PGCs.

15 47. The method according to claim 38, wherein the administering step is carried out by injecting the recipient bird of the first avian species with blastodermal cells, and wherein the blastodermal cells differentiate into donor PGCs in the recipient bird of the first avian species.

20 48. A method for enhancing germ line transmission of a nucleic acid molecule in a bird, the method comprising:

- (a) immunizing a female bird with an antigen associated with primordial germ cells, whereby an egg produced by the female bird comprises a sufficiently high concentration of antibodies specific for the antigen to modulate PGC development in a recipient bird present within the egg;
- (b) administering a plurality of donor PGCs comprising the nucleic acid molecule to the recipient bird under conditions sufficient to allow at least one of the plurality of PGCs to colonize a gonad of the recipient bird;
- (c) incubating the recipient bird to hatch; and
- (d) raising the recipient bird to sexual maturity, wherein the

recipient bird produces gametes derived from the donor PGCs.

49. The method of Claim 48, wherein the antigen comprises an epitope of a polypeptide is selected from the group consisting of SSEA-1, VASA, EMA-1, germ cell-less, dead end, nanos, stella, fragilis, and DAZL.

5 50. The method according to Claim 48, wherein the recipient bird and the donor PGCs are each selected from the group consisting of chicken, turkey, duck, quail, sand hill crane, and whooping crane.

51. The method according to Claim 48, wherein the donor PGCs are from the same avian species as the recipient bird.

10 52. The method according to Claim 48, wherein the donor PGCs are from a different avian species as the recipient bird.

53. The method according to Claim 48, wherein the administering is by *in ovo* injection.


15 54. The method according to Claim 48, wherein the donor PGCs are administered when the recipient bird is between about stage IX according to the Eyal-Giladi & Kochav staging system and about stage 30 according to the Hamburger & Hamilton staging system.

20 55. The method according to Claim 48, wherein the donor PGCs are administered when the recipient bird is after stage 14 according to the Hamburger & Hamilton staging system.


56. The method according to Claim 48, wherein the PGCs are selected from the group consisting of gonadal PGCs, blood PGCs, and germinal crescent PGCs.

25 57. The method according to claim 48, wherein the administering step is carried out by injecting the recipient bird with blastodermal cells, and wherein the blastodermal cells differentiate into donor PGCs in the recipient bird.


1/4

**FIGURE 1**

2/4

**FIGURE 2**

3/4

**FIGURE 3**

4/4

**Number of Gonadal PGCs in Stage 27 Embryos
17 Days After Immunization**




FIGURE 4

SEQUENCE LISTING

<110> North Carolina State University
 5 Petitte, James
 Pardue, Samuel
 <120> DEPLETION OF ENDOGENOUS PRIMORDIAL GERM CELLS IN AVIAN SPECIES
 10 <130> 297/204 PCT
 <150> US 60/440,424
 <151> 2003-01-16
 15 <160> 8
 <170> PatentIn version 3.2
 20 <210> 1
 <211> 1989
 <212> DNA
 <213> Gallus gallus
 <220>
 25 <221> CDS
 <222> (1)..(1989)
 <400> 1
 atg gag gag gac tgg gac acg gag ctg gag cag gag gcg gca gcg gct 48
 Met Glu Glu Asp Trp Asp Thr Glu Leu Glu Gln Glu Ala Ala Ala Ala
 30 1 5 10 15
 tcc cag ggg cgt tct gag gag cag gcg tgg atg gct aac tct ggc aga 96
 Ser Gln Gly Arg Ser Glu Glu Gln Ala Trp Met Ala Asn Ser Gly Arg
 35 20 25 30
 cca aac agc cca tcc ctc cgc ttc tcc agc aga cca agc agc ccc ttg 144
 Pro Asn Ser Pro Ser Leu Arg Phe Ser Ser Arg Pro Ser Ser Pro Leu
 40 35 40 45
 tct ggc ttc cca ggc aga cca aac agc ccc ttc ttt ggc ttt agt cag 192
 Ser Gly Phe Pro Gly Arg Pro Asn Ser Pro Phe Phe Gly Phe Ser Gln
 45 50 55 60
 aat aaa ggc tca ctt ggt gct aat gaa gga ctt aac aga agt ctg cct 240
 Asn Lys Gly Ser Leu Gly Ala Asn Glu Gly Leu Asn Arg Ser Leu Pro
 50 65 70 75 80
 gtg cag cat gac att gga gga tat tct ggg agc aga gag tct gtt gta 288
 Val Gln His Asp Ile Gly Tyr Ser Gly Ser Arg Glu Ser Val Val
 55 85 90 95
 cgt caa aac aga gaa gat caa cca gtg act aga ttt ggt aga ggg agg 336
 Arg Gln Asn Arg Glu Asp Gln Pro Val Thr Arg Phe Gly Arg Gly Arg
 60 100 105 110
 agt tct gga agc aga gat ttt caa gag agg aac tct gca aat gat cct 384
 Ser Ser Gly Ser Arg Asp Phe Gln Glu Arg Asn Ser Ala Asn Asp Pro
 65 115 120 125
 ggt atg caa gat caa ggt ttt aga aga gtt cct ggc atc ttt ggg caa 432
 Gly Met Gln Asp Gln Gly Phe Arg Arg Val Pro Gly Ile Phe Gly Gln
 70 130 135 140

	agc aag tgt ttt aac agt gag gaa aga aat agt cct ctg cgt ggc agc Ser Lys Cys Phe Asn Ser Glu Glu Arg Asn Ser Pro Leu Arg Gly Ser 145 150 155 160	480
5	cct ttt gcc cca gga gga aga gga gca gtt gga ggt cct gca gga gtt Pro Phe Ala Pro Gly Gly Arg Gly Ala Val Gly Gly Pro Ala Gly Val 165 170 175	528
10	ctc aaa gga cgc tct gaa gaa att gat tct gga aga ggt cca aag gtg Leu Lys Gly Arg Ser Glu Glu Ile Asp Ser Gly Arg Gly Pro Lys Val 180 185 190	576
15	act tat gtc ccc cct cct cca cct gaa gat gaa cag tcc atc ttt gca Thr Tyr Val Pro Pro Pro Pro Glu Asp Glu Gln Ser Ile Phe Ala 195 200 205	624
20	tgt tat cag tca gga att aat ttt gac aag tat gat gaa tgt gct gtt Cys Tyr Gln Ser Gly Ile Asn Phe Asp Lys Tyr Asp Glu Cys Ala Val 210 215 220	672
	gag atg tca gga ctt gac cct cca gca cca tta ctg gct ttt gaa gaa Glu Met Ser Gly Leu Asp Pro Pro Ala Pro Leu Leu Ala Phe Glu Glu 225 230 235 240	720
25	gct aac ttt gct cag act tta agg aag aat ata tct aaa act gga tat Ala Asn Phe Ala Gln Thr Leu Arg Lys Asn Ile Ser Lys Thr Gly Tyr 245 250 255	768
30	tca aaa ctt act cca gtg cag aag cac agc att cct gtt ata caa gca Ser Lys Leu Thr Pro Val Gln Lys His Ser Ile Pro Val Ile Gln Ala 260 265 270	816
35	ggg cgg gat tta atg tca tgt gcc cag aca gga tca gga aaa aca gca Gly Arg Asp Leu Met Ser Cys Ala Gln Thr Gly Ser Gly Lys Thr Ala 275 280 285	864
40	gct ttt ctt cta cca att gtg gac cgg atg atg aaa gat ggt gta act Ala Phe Leu Leu Pro Ile Val Asp Arg Met Met Lys Asp Gly Val Thr 290 295 300	912
	gca agc ttc cca aag cag caa gac cca caa tgc att att gtt gca cca Ala Ser Phe Pro Lys Gln Gln Asp Pro Gln Cys Ile Ile Val Ala Pro 305 310 315 320	960
45	act aga gaa ctg ata aat cag atc ttc tta gaa gca agg aag ttt gtg Thr Arg Glu Leu Ile Asn Gln Ile Phe Leu Glu Ala Arg Lys Phe Val 325 330 335	1008
50	tat ggg act tgt ata agg cct gtt gtg atc tat gga ggt aca cag aca Tyr Gly Thr Cys Ile Arg Pro Val Val Ile Tyr Gly Gly Thr Gln Thr 340 345 350	1056
	ggt cat tca atc cgt caa ata atg caa ggc tgt aat ata tta tgt gcc Gly His Ser Ile Arg Gln Ile Met Gln Gly Cys Asn Ile Leu Cys Ala 355 360 365	1104
55	act cct gga agg ctt ctt gac att att gaa aaa ggg aag atc agt ttg Thr Pro Gly Arg Leu Leu Asp Ile Ile Glu Lys Gly Lys Ile Ser Leu 370 375 380	1152
60	gtg gag gtg aaa tat ttg gta cta gat gaa gca gac cgc atg ctc gat Val Glu Val Lys Tyr Leu Val Leu Asp Glu Ala Asp Arg Met Leu Asp 385 390 395 400	1200

	atg ggt ttt gga tta gat atg aag aag ctg att tct tat cca gaa atg Met Gly Phe Gly Leu Asp Met Lys Lys Leu Ile Ser Tyr Pro Glu Met 405 410 415	1248
5	cca tct aaa gac aga cgt caa aca tta atg ttt agt gcc act ttt cct Pro Ser Lys Asp Arg Arg Gln Thr Leu Met Phe Ser Ala Thr Phe Pro 420 425 430	1296
10	gag gaa gtt caa agg ctg gct ggt gaa ttt ttg aaa acg gac tat ata Glu Glu Val Gln Arg Leu Ala Gly Glu Phe Leu Lys Thr Asp Tyr Ile 435 440 445	1344
15	ttt ctt gtt att gga aat acc tgt gga gcc tgc agt gat gtt cag caa Phe Leu Val Ile Gly Asn Thr Cys Gly Ala Cys Ser Asp Val Gln Gln 450 455 460	1392
20	aat att ctt cag gtt ccc cg ^g tta tcc aag agg gat aaa cta ata gaa Asn Ile Leu Gln Val Pro Arg Leu Ser Lys Arg Asp Lys Leu Ile Glu 465 470 475 480	1440
	att cta caa agc aca ggt ggt gaa cga acc atg gtg ttt gtg gac aca Ile Leu Gln Ser Thr Gly Glu Arg Thr Met Val Phe Val Asp Thr 485 490 495	1488
25	aag aaa aaa gca gat tac ctt gca gcc ttt ctt tgt caa gag aac cta Lys Lys Lys Ala Asp Tyr Leu Ala Ala Phe Leu Cys Gln Glu Asn Leu 500 505 510	1536
30	cca tcc acc agc att cat gga gat agg gaa cag aga gag aga gag ata Pro Ser Thr Ser Ile His Gly Asp Arg Glu Gln Arg Glu Arg Glu Ile 515 520 525	1584
35	gct ctt cgc gat ttc cgt tct gga aaa tgt caa att ctt gtg gca act Ala Leu Arg Asp Phe Arg Ser Gly Lys Cys Gln Ile Leu Val Ala Thr 530 535 540	1632
40	tcg gta gca tca aga ggc ctg gat att gaa aat gtt caa cat gtt att Ser Val Ala Ser Arg Gly Leu Asp Ile Glu Asn Val Gln His Val Ile 545 550 555 560	1680
	aat ttt gat ctc cct aac acc att gaa gat tat gta cat cga att gga Asn Phe Asp Leu Pro Asn Thr Ile Glu Asp Tyr Val His Arg Ile Gly 565 570 575	1728
45	cga act ggt cgt tgt gga aat act ggc aaa gca gtt tca ttc ttt gat Arg Thr Gly Arg Cys Gly Asn Thr Gly Lys Ala Val Ser Phe Phe Asp 580 585 590	1776
50	gat cag tca gat ggc cat ctt gta caa tca cta ctt aaa gtg ctt tcc Asp Gln Ser Asp Gly His Leu Val Gln Ser Leu Leu Lys Val Leu Ser 595 600 605	1824
55	aga acc cag cag gaa ttc cag ttt ggt gga aga atg gct gtc caa aga Arg Thr Gln Gln Glu Phe Gln Phe Gly Gly Arg Met Ala Val Gln Arg 610 615 620	1872
60	aca aat att gtt gct tca act tgg tgc cca aag gga tta atg cag gcc Thr Asn Ile Val Ala Ser Thr Trp Cys Pro Lys Gly Leu Met Gln Ala 625 630 635 640	1920
	gtg gca gaa tgg aac cca aga gaa atg agg atg tca tat tct gaa aca Val Ala Glu Trp Asn Pro Arg Glu Met Arg Met Ser Tyr Ser Glu Thr 645 650 655	1968

1989

	aca ttt aag tca tgg gag taa	
	Thr Phe Lys Ser Trp Glu	
	660	
5	<210> 2	
	<211> 662	
	<212> PRT	
	<213> Gallus gallus	
10	<400> 2	
	Met Glu Glu Asp Trp Asp Thr Glu Leu Glu Gln Glu Ala Ala Ala Ala	
	1 5 10 15	
15	Ser Gln Gly Arg Ser Glu Glu Gln Ala Trp Met Ala Asn Ser Gly Arg	
	20 25 30	
	Pro Asn Ser Pro Ser Leu Arg Phe Ser Ser Arg Pro Ser Ser Pro Leu	
20	35 40 45	
	Ser Gly Phe Pro Gly Arg Pro Asn Ser Pro Phe Phe Gly Phe Ser Gln	
	50 55 60	
25	Asn Lys Gly Ser Leu Gly Ala Asn Glu Gly Leu Asn Arg Ser Leu Pro	
	65 70 75 80	
	Val Gln His Asp Ile Gly Gly Tyr Ser Gly Ser Arg Glu Ser Val Val	
	85 90 95	
30	Arg Gln Asn Arg Glu Asp Gln Pro Val Thr Arg Phe Gly Arg Gly Arg	
	100 105 110	
	Ser Ser Gly Ser Arg Asp Phe Gln Glu Arg Asn Ser Ala Asn Asp Pro	
35	115 120 125	
	Gly Met Gln Asp Gln Gly Phe Arg Arg Val Pro Gly Ile Phe Gly Gln	
	130 135 140	
40	Ser Lys Cys Phe Asn Ser Glu Glu Arg Asn Ser Pro Leu Arg Gly Ser	
	145 150 155 160	
	Pro Phe Ala Pro Gly Gly Arg Gly Ala Val Gly Gly Pro Ala Gly Val	
	165 170 175	
45	Leu Lys Gly Arg Ser Glu Glu Ile Asp Ser Gly Arg Gly Pro Lys Val	
	180 185 190	
	Thr Tyr Val Pro Pro Pro Pro Glu Asp Glu Gln Ser Ile Phe Ala	
50	195 200 205	
	Cys Tyr Gln Ser Gly Ile Asn Phe Asp Lys Tyr Asp Glu Cys Ala Val	
	210 215 220	
55	Glu Met Ser Gly Leu Asp Pro Pro Ala Pro Leu Leu Ala Phe Glu Glu	
	225 230 235 240	
	Ala Asn Phe Ala Gln Thr Leu Arg Lys Asn Ile Ser Lys Thr Gly Tyr	
	245 250 255	
60	Ser Lys Leu Thr Pro Val Gln Lys His Ser Ile Pro Val Ile Gln Ala	
	260 265 270	
	Gly Arg Asp Leu Met Ser Cys Ala Gln Thr Gly Ser Gly Lys Thr Ala	
	275 280 285	

	Ala Phe Leu Leu Pro Ile Val Asp Arg Met Met Lys Asp Gly Val Thr			
	290	295	300	
5	Ala Ser Phe Pro Lys Gln Gln Asp Pro Gln Cys Ile Ile Val Ala Pro			
	305	310	315	320
	Thr Arg Glu Leu Ile Asn Gln Ile Phe Leu Glu Ala Arg Lys Phe Val			
	325	330	335	
10	Tyr Gly Thr Cys Ile Arg Pro Val Val Ile Tyr Gly Gly Thr Gln Thr			
	340	345	350	
15	Gly His Ser Ile Arg Gln Ile Met Gln Gly Cys Asn Ile Leu Cys Ala			
	355	360	365	
	Thr Pro Gly Arg Leu Leu Asp Ile Ile Glu Lys Gly Lys Ile Ser Leu			
	370	375	380	
20	Val Glu Val Lys Tyr Leu Val Leu Asp Glu Ala Asp Arg Met Leu Asp			
	385	390	395	400
25	Met Gly Phe Gly Leu Asp Met Lys Lys Leu Ile Ser Tyr Pro Glu Met			
	405	410	415	
	Pro Ser Lys Asp Arg Arg Gln Thr Leu Met Phe Ser Ala Thr Phe Pro			
	420	425	430	
30	Glu Glu Val Gln Arg Leu Ala Gly Glu Phe Leu Lys Thr Asp Tyr Ile			
	435	440	445	
	Phe Leu Val Ile Gly Asn Thr Cys Gly Ala Cys Ser Asp Val Gln Gln			
	450	455	460	
35	Asn Ile Leu Gln Val Pro Arg Leu Ser Lys Arg Asp Lys Leu Ile Glu			
	465	470	475	480
40	Ile Leu Gln Ser Thr Gly Gly Glu Arg Thr Met Val Phe Val Asp Thr			
	485	490	495	
	Lys Lys Lys Ala Asp Tyr Leu Ala Ala Phe Leu Cys Gln Glu Asn Leu			
	500	505	510	
45	Pro Ser Thr Ser Ile His Gly Asp Arg Glu Gln Arg Glu Arg Glu Ile			
	515	520	525	
	Ala Leu Arg Asp Phe Arg Ser Gly Lys Cys Gln Ile Leu Val Ala Thr			
	530	535	540	
50	Ser Val Ala Ser Arg Gly Leu Asp Ile Glu Asn Val Gln His Val Ile			
	545	550	555	560
55	Asn Phe Asp Leu Pro Asn Thr Ile Glu Asp Tyr Val His Arg Ile Gly			
	565	570	575	
	Arg Thr Gly Arg Cys Gly Asn Thr Gly Lys Ala Val Ser Phe Phe Asp			
	580	585	590	
60	Asp Gln Ser Asp Gly His Leu Val Gln Ser Leu Leu Lys Val Leu Ser			
	595	600	605	
	Arg Thr Gln Gln Glu Phe Gln Phe Gly Gly Arg Met Ala Val Gln Arg			
	610	615	620	

Thr Asn Ile Val Ala Ser Thr Trp Cys Pro Lys Gly Leu Met Gln Ala
 625 630 635 640

5 Val Ala Glu Trp Asn Pro Arg Glu Met Arg Met Ser Tyr Ser Glu Thr
 645 650 655

Thr Phe Lys Ser Trp Glu
 660

10 <210> 3
 <211> 16
 <212> PRT
 <213> Gallus gallus

15 <400> 3

Ser Arg Pro Ser Ser Pro Leu Ser Gly Phe Pro Gly Arg Pro Asn Ser
 1 5 10 15

20 <210> 4
 <211> 16
 <212> PRT
 <213> Gallus gallus

25 <400> 4

Asn Pro Arg Glu Met Arg Met Ser Tyr Ser Glu Thr Thr Phe Lys Ser
 1 5 10 15

30 <210> 5
 <211> 1882
 <212> DNA
 <213> Gallus gallus

35 <220>
 <221> CDS
 <222> (174)..(1043)

40 <400> 5
 ccttttcac acccctctta aaaaagaaaa gaaagaaaaa aaagacaaaa aaaaatacaa 60
 acacaaaaaa gtggggttct ttagtatctg ttttcccaac actcctattg ttttgtctt 120

45 gaaggcctcg ttgtttta agtgtgcggg cgctgtcaca gctccgggaa acg atg 176
 Met
 1

50 tct gca aat gcg gaa gcc cag tgt gga agt atc tca gag gat aat acc 224
 Ser Ala Asn Ala Glu Ala Gln Cys Gly Ser Ile Ser Glu Asp Asn Thr
 5 10 15

55 cat tcg tca aca acc tgc caa gga tat gtt tta cca gaa gga aaa atc 272
 His Ser Ser Thr Thr Cys Gln Gly Tyr Val Leu Pro Glu Gly Lys Ile
 20 25 30

60 atg cca aat aca gtc ttt gtt ggt gga att gat ata agg atg aat gaa 320
 Met Pro Asn Thr Val Phe Val Gly Gly Ile Asp Ile Arg Met Asn Glu
 35 40 45

gca gaa att cgg agt tac ttt gaa caa tat ggt act gtg aag gag gtg 368
 Ala Glu Ile Arg Ser Tyr Phe Glu Gln Tyr Gly Thr Val Lys Glu Val
 50 55 60 65

	aaa ata atc act gac aga act ggt gtt tcc aaa ggg tat gga ttt gtt	416
	Lys Ile Ile Thr Asp Arg Thr Gly Val Ser Lys Gly Tyr Gly Phe Val	
	70 75 80	
5	tca ttc ctg gac aat gtg gat gtt caa aag ata gta gaa tca cag atc	464
	Ser Phe Leu Asp Asn Val Asp Val Gln Lys Ile Val Glu Ser Gln Ile	
	85 90 95	
10	agt gtc cat gga aaa agg ctg aaa ctg gga cca gca att aga aaa caa	512
	Ser Val His Gly Lys Arg Leu Lys Leu Gly Pro Ala Ile Arg Lys Gln	
	100 105 110	
15	caa aac ttg tgt tct tac atg cag cct aga cca ttg gct ttc aat cct	560
	Gln Asn Leu Cys Ser Tyr Met Gln Pro Arg Pro Leu Ala Phe Asn Pro	
	115 120 125	
20	cct gca ccg caa ttc cat agc gta tgg act aat caa aat aca gag acc	608
	Pro Ala Pro Gln Phe His Ser Val Trp Thr Asn Gln Asn Thr Glu Thr	
	130 135 140 145	
25	tac gtg cag cct caa gct gtg gtg agc cca cta act cag tat gtc cag	656
	Tyr Val Gln Pro Gln Ala Val Val Ser Pro Leu Thr Gln Tyr Val Gln	
	150 155 160	
30	acg tat gcg tac agt tca cca gct gta ttg ata cag cag caa gtt cct	704
	Thr Tyr Ala Tyr Ser Ser Pro Ala Val Leu Ile Gln Gln Val Pro	
	165 170 175	
35	gta gga tat cag cca gca tac aac tat cag gct cca cca cag tgg gtt	752
	Val Gly Tyr Gln Pro Ala Tyr Asn Tyr Gln Ala Pro Pro Gln Trp Val	
	180 185 190	
40	cct ggg gag caa aga aac tac gtt atg cct ccg gtt tat act tca gta	800
	Pro Gly Glu Gln Arg Asn Tyr Val Met Pro Pro Val Tyr Thr Ser Val	
	195 200 205	
45	aac tat cac tac agt gag gat cca gaa ttt ata caa aca gaa tgt gct	848
	Asn Tyr His Tyr Ser Glu Asp Pro Glu Phe Ile Gln Thr Glu Cys Ala	
	210 215 220 225	
50	gtc cca gag ccc aca cag atg tct ggt aat agt cca caa aaa aag tct	896
	Val Pro Glu Pro Thr Gln Met Ser Gly Asn Ser Pro Gln Lys Lys Ser	
	230 235 240	
55	gtg gac agg agc ata caa aca gta gta tcc tgt ctg ttt aac cct gaa	944
	Val Asp Arg Ser Ile Gln Thr Val Val Ser Cys Leu Phe Asn Pro Glu	
	245 250 255	
60	aac cgt ctg agg aac acc ttt gta tca caa gaa gac tac ttc agg gag	992
	Asn Arg Leu Arg Asn Thr Phe Val Ser Gln Glu Asp Tyr Phe Arg Glu	
	260 265 270	
65	agg agg gcg cat cac ttc aga aaa gga aga gca gtg ctc aaa agt gtt	1040
	Arg Arg Ala His His Phe Arg Lys Gly Arg Ala Val Leu Lys Ser Val	
	275 280 285	
70	tga tgaacaaaga ctttgaagta cataaatgta ttactttgat gttcctacag	1093
	ttcagtttag taagatgtgt agtaaaaagt gtaaccttgt tcaaaaaagtt gcttcaagtt	1153
	gatgtttgtg ttctgtttta cctgttccag aatagctatt tttgcttgag aagtttgaag	1213
	ttgtaagagt tgaaatattt ccaggtttta ttactagctt gcatgcttt cctgctaact	1273

aactgaaatg ctaatctaa ggaatttata tggggaaaggg gaaaaaagaa aaacactttg 1333
 tttggtatgt gtggatttc ttctgagctt taaggtacag tttgttgcattt gttaaaattt 1393
 5 agttcttatt aaaccacaac tttaagttac taacgtcaac cagttaccc tcgcagttca 1453
 aaagttgaag cagttccttgc tccaagatgg agtattttaa aactgagctc ttaatcagtg 1513
 10 gaacagaaga cgtcacggtg taactcaact gaagccctt aagtcccggt tctctttaga 1573
 ctacctaatac aatgtctttg tttgctaactc acagttcatc tatgtgaatc ctaaaattcc 1633
 tataatgttaac ttaagatgca agaatgtaat tagttacatt ggctgctcag tggagtatga 1693
 15 ctttttttt tactggatta attttagcaa tacctgtatc ttaaaattgt gagaaaatac 1753
 tgcatataaa atatgcctaa ctttgcacg caatatgtta atcaaagaat acatgtaaac 1813
 20 atatttaaa aataattatg tagattttag tcacgtatc tgaaacaatt aaaattttt 1873
 attttgact 1882

<210> 6
 <211> 289
 25 <212> PRT
 <213> Gallus gallus

<400> 6

30 Met Ser Ala Asn Ala Glu Ala Gln Cys Gly Ser Ile Ser Glu Asp Asn
 1 5 10 15

Thr His Ser Ser Thr Thr Cys Gln Gly Tyr Val Leu Pro Glu Gly Lys
 20 25 30

35 Ile Met Pro Asn Thr Val Phe Val Gly Gly Ile Asp Ile Arg Met Asn
 35 40 45

40 Glu Ala Glu Ile Arg Ser Tyr Phe Glu Gln Tyr Gly Thr Val Lys Glu
 50 55 60

Val Lys Ile Ile Thr Asp Arg Thr Gly Val Ser Lys Gly Tyr Gly Phe
 65 70 75 80

45 Val Ser Phe Leu Asp Asn Val Asp Val Gln Lys Ile Val Glu Ser Gln
 85 90 95

Ile Ser Val His Gly Lys Arg Leu Lys Leu Gly Pro Ala Ile Arg Lys
 100 105 110

50 Gln Gln Asn Leu Cys Ser Tyr Met Gln Pro Arg Pro Leu Ala Phe Asn
 115 120 125

55 Pro Pro Ala Pro Gln Phe His Ser Val Trp Thr Asn Gln Asn Thr Glu
 130 135 140

Thr Tyr Val Gln Pro Gln Ala Val Val Ser Pro Leu Thr Gln Tyr Val
 145 150 155 160

60 Gln Thr Tyr Ala Tyr Ser Ser Pro Ala Val Leu Ile Gln Gln Val
 165 170 175

Pro Val Gly Tyr Gln Pro Ala Tyr Asn Tyr Gln Ala Pro Pro Gln Trp
 180 185 190

Val Pro Gly Glu Gln Arg Asn Tyr Val Met Pro Pro Val Tyr Thr Ser
195 200 205

5 val Asn Tyr His Tyr Ser Glu Asp Pro Glu Phe Ile Gln Thr Glu Cys
210 215 220

Ala Val Pro Glu Pro Thr Gln Met Ser Gly Asn Ser Pro Gln Lys Lys
10 225 230 235 240

Ser Val Asp Arg Ser Ile Gln Thr Val Val Ser Cys Leu Phe Asn Pro
245 250 255

Glu Asn Arg Leu Arg Asn Thr Phe Val Ser Gln Glu Asp Tyr Phe Arg
15 260 265 270

Glu Arg Arg Ala His His Phe Arg Lys Gly Arg Ala Val Leu Lys Ser
275 280 285

20 Val

<210> 7
25 <211> 17
<212> PRT
<213> Gallus gallus

<400> 7

30 Ser Ala Asn Ala Glu Ala Gln Cys Gly Ser Ile Ser Glu Asp Asn Thr
1 5 10 15

His

35

<210> 8
40 <211> 16
<212> PRT
<213> Gallus gallus

<400> 8

45 Ser Gln Glu Asp Tyr Phe Arg Glu Arg Ala His His Phe Arg Lys Gly
1 5 10 15